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Summary of findings {#CD008625-sec1-0001}
===================

Summary of findings for the main comparisonAntimicrobial drugs versus placebo/no treatment for treating cholera**Antimicrobial drugs versus placebo/no treatment for treating choleraPatient or population:** Adults and children with cholera diarrhoea **Intervention:** Antimicrobial drugs **Comparison:** Placebo/no treatment**OutcomesIllustrative comparative risks\* (95% CI)Relative effect (95% CI)No of participants (studies)Quality of the evidence (GRADE)CommentsAssumed riskCorresponding riskPlacebo/no treatmentAntimicrobial drugsDiarrhoea duration**The mean duration of diarrhoea in the control groups ranged from **29.3 to 127.2 hours**The mean duration of diarrhoea in the intervention groups was **36.77 hours shorter** (43.51 to 30.03 hours shorter)1013 (19 studies)⊕⊕⊕⊝ **moderate** ^1,2,3,4^**Stool volume**The median volume across control groups was 13.5 litres for adults and 368 ml/kg for childrenThe corresponding volume with antibiotics would be 7.3 litres for adults (6.1 to 7.6 L), and 184 mL/kg for children (166 to 206 mL/kg)**ROM 0.50** (0.45 to 0.56)1042 (18 studies)⊕⊕⊕⊝ **moderate**^1,2,3,4^**Hydration fluid requirements**The median volume across control groups was 14 litres for adults and 374 mL/kg for childrenThe corresponding volume with antibiotics would be 8.4 litres for adults (7.4 to 9.5 L), and 224 mL/kg for children (198 to 254 mL/kg)**ROM 0.60** (0.53 to 0.68)1201\
(11 studies)⊕⊕⊕⊝ **moderate**^1,2,3,4^**Duration of pathogen secretion**The mean duration of pathogen secretion in the control groups ranged from **2.97 to 6.0 days**The mean duration of pathogen secretion in the intervention groups was **2.74 days shorter** (3.07 to 2.40 days shorter)740 (12 studies)⊕⊕⊕⊝ **moderate**^5,2,3,4^**Deaths‐‐**See comment299 (7 studies)‐No deaths occurred in these studies\*The basis for the **assumed risk** (eg the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **CI:** Confidence interval; **RR:** Risk ratio; **ROM**: Ratio of means.GRADE Working Group grades of evidence **High quality:** Further research is very unlikely to change our confidence in the estimate of effect. **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low quality:** We are very uncertain about the estimate.[^2]

Summary of findings 2Azithromycin versus ciprofloxacin for treating cholera**Azithromycin versus ciprofloxacin for treating choleraPatient or population:** Adults and children with cholera diarrhoea **Intervention:** Azithromycin (single dose of 1 g or 20 mg/kg) **Comparison:** Ciprofloxacin (single dose of 1 g or 20 mg/kg)**OutcomesIllustrative comparative risks\* (95% CI)Relative effect (95% CI)No of participants (studies)Quality of the evidence (GRADE)Assumed riskCorresponding riskCiprofloxacinAzithromycinDiarrhoea duration**The mean duration of diarrhoea in the control groups ranged from\
**71.5 to 78 hours**The mean duration of diarrhoea in the intervention groups was **32.43 hours shorter** (62.9 to 1.95 hours shorter)375 (2 studies)⊕⊕⊕⊝ **moderate**^1,2,3,4^**Stool volume**The median volume across control groups was **322 mL/kg**The corresponding volume with azithromycin would be **113 ml/kg** (90 to 142 mL/kg)**ROM 0.35** (0.28 to 0.44)195 (1 study)⊕⊕⊝⊝ **low**^5,6,7^**Bacteriological failure492 per 1000113 per 1000** (79 to 167 per 1000)**RR 0.23** (0.16 to 0.34)375 (2 studies)⊕⊕⊝⊝ **low**^1,8,3,7^\*The basis for the **assumed risk** (eg the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **CI:** Confidence interval; **RR:** Risk ratio; **ROM**: Ratio of means.GRADE Working Group grades of evidence **High quality:** Further research is very unlikely to change our confidence in the estimate of effect. **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low quality:** We are very uncertain about the estimate.[^3]

Summary of findings 3Azithromycin versus erythromycin for treating cholera**Azithromycin versus erythromycin for treating choleraPatient or population:** Adults and children with cholera diarrhoea **Intervention:** Azithromycin (20 mg/kg single dose, one trial; 10 mg/kg once daily for three days, one trial) **Comparison:** Erythromycin (12.5 mg/kg four times daily for three days, both trials)**OutcomesIllustrative comparative risks\* (95% CI)Relative effect (95% CI)No of participants (studies)Quality of the evidence (GRADE)Assumed riskCorresponding riskErythromycinAzithromycinDiarrhoea duration**The mean duration of diarrhoea in the control groups ranged from **33.5 to 42.0 hours**The mean duration of diarrhoea in the intervention groups was **12.05 hours shorter** (22.02 to 2.08 hours shorter)179 (2 studies)⊕⊕⊕⊝ **moderate**^1,2,3,4^**Stool volume**The median volume across control groups was **3.1 litres in adults or 186 mL/kg in children**The corresponding volume with azithromycin would be **2.1 litres in adults** (1.7 to 2.6 litres), or **128 mL/kg in children** (104 to 158 mL/kg)**ROM 0.69** (0.56 to 0.85)172 (2 studies)⊕⊕⊕⊝ **moderate**^1,3,4,5^**Bacteriological failure126 per 1000197 per 1000** (101 to 381 per 1000)**RR 1.56** (0.80 to 3.02)179 (2 studies)⊕⊕⊝⊝ **low**^1,3,6^\*The basis for the **assumed risk** (eg the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **CI:** Confidence interval; **RR:** Risk ratio; **ROM**: Ratio of means.GRADE Working Group grades of evidence **High quality:** Further research is very unlikely to change our confidence in the estimate of effect. **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low quality:** We are very uncertain about the estimate.[^4]

Summary of findings 4Tetracycline versus doxycycline for treating cholera**Tetracycline versus doxycycline for treating choleraPatient or population:** Adults and children with cholera diarrhoea **Intervention:** Tetracycline (four times daily for two to four days) **Comparison:** Doxycycline (300 mg total dose given over one to three days)**OutcomesIllustrative comparative risks\* (95% CI)Relative effect (95% CI)No of participants (studies)Quality of the evidence (GRADE)Assumed riskCorresponding riskDoxycyclineTetracyclineDiarrhoea duration**The mean duration of diarrhoea in the control groups ranged from **15 to 32 hours**The mean duration of diarrhoea in the intervention groups was **2.01 hours shorter** (8.21 hours shorter to 4.19 hours longer)230 (3 studies)⊕⊕⊕⊝ **moderate**^1,2,3,4^**Stool volume**The median volume across control groups was**3 litres**The corresponding volume with tetracycline would be **2.9 litres** (2.5 to 3.4 litres)**ROM 0.97** (0.83 to 1.14)336 (3 studies)⊕⊕⊕⊝ **moderate**^1,2,3,4^**Bacteriological failure153 per 100031 per 1000** (9 to 104 per 1000)**RR 0.2** (0.06 to 0.68)198 (2 studies)⊕⊕⊕⊝ **moderate**^5,6^\*The basis for the **assumed risk** (eg the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **CI:** Confidence interval; **RR:** Risk ratio; **ROM**: Ratio of means.GRADE Working Group grades of evidence **High quality:** Further research is very unlikely to change our confidence in the estimate of effect. **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low quality:** We are very uncertain about the estimate.[^5]

Summary of findings 5Tetracycline versus quinolones for treating cholera**Tetracycline versus quinolones for treating choleraPatient or population:** Adults and children with cholera diarrhoea **Intervention:** Tetracycline (500 mg four times daily for three days) **Comparison:** Quinolone (Ciprofloxacin 1 g single dose or 250 mg once daily for three days, or norfloxacin 400 mg twice daily for three days)**OutcomesIllustrative comparative risks\* (95% CI)Relative effect (95% CI)No of participants (studies)Quality of the evidence (GRADE)Assumed riskCorresponding riskQuinoloneTetracyclineDiarrhoea duration**The mean duration of diarrhoea in the control groups ranged from **30 to 51 hours**The mean duration of diarrhoea in the intervention groups was **0.91 hours shorter** (4.53 hours shorter to 2.72 hours longer)259 (3 studies)⊕⊕⊕⊝ **moderate**^1,2,3,4^**Stool volume**The median volume across control groups was **215 mL/kg**The corresponding volume with tetracycline would be **187 ml/kg** (161 to 219 mL/kg)**ROM 0.87** (0.75 to 1.02)236 (2 studies)⊕⊕⊝⊝ **low**^1,2,5^**Bacteriological failure9 per 10009 per 1000** (1 to 59 per 1000)**RR 0.99** (0.14 to 6.82)234 (2 studies)⊕⊕⊝⊝ **low**^1,2,6^\*The basis for the **assumed risk** (eg the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **CI:** Confidence interval; **RR:** Risk ratio; **ROM**: Ratio of means.GRADE Working Group grades of evidence **High quality:** Further research is very unlikely to change our confidence in the estimate of effect. **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low quality:** We are very uncertain about the estimate.[^6]

Summary of findings 6Doxycycline versus quinolones for treating cholera**Doxycycline versus quinolones for treating choleraPatient or population:** Adults and children with cholera diarrhoea **Intervention:** Doxycycline (300 mg single dose or 100 mg twice daily for three days) **Comparison:** Quinolones (Ciprofloxacin 1 g single dose or norfloxacin 800 mg single dose or norfloxacin 400 mg BD for three days)**OutcomesIllustrative comparative risks\* (95% CI)Relative effect (95% CI)No of participants (studies)Quality of the evidence (GRADE)Assumed riskCorresponding riskQuinolonesDoxycyclineDiarrhoea duration**The mean duration of diarrhoea in the control groups ranged from **35 to 60 hours**The mean diarrhoea duration in the intervention groups was **4.64 hours longer** (2.14 hours shorter to 11.42 hours longer)126 (3 studies)⊕⊕⊝⊝ **low**^1,2,3,4^**Stool volume**The median volume across control groups was **148 mL/kg**The corresponding volume with doxycycline would be **149 mL/kg** (121 to 185 mL/kg)**ROM 1.01** (0.82 to 1.25)435 (4 studies)⊕⊕⊝⊝ **low**^5,3,6^**Bacteriological failure32 per 1000188 per 1000** (87 to 408 per 1000)**RR 5.84** (2.7 to 12.65)386 (4 studies)⊕⊕⊝⊝ **low**^5,3,6^\*The basis for the **assumed risk** (eg the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **CI:** Confidence interval; **RR:** Risk ratio; **ROM**: Ratio of means.GRADE Working Group grades of evidence **High quality:** Further research is very unlikely to change our confidence in the estimate of effect. **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low quality:** We are very uncertain about the estimate.[^7]

Summary of findings 7Short compared to long duration of antimicrobials for treating cholera**Short compared to Long duration of antimicrobials for choleraPatient or population:** Adults and children with cholera diarrhoea **Intervention:** Short duration of treatment **Comparison:** Long duration of treatment**OutcomesIllustrative comparative risks\* (95% CI)Relative effect (95% CI)No of participants (studies)Quality of the evidence (GRADE)Assumed riskCorresponding riskLong durationShort durationDiarrhoea duration**‐‐**MD 0.34** (‐4.65 to 5.32)431 (7 studies)⊕⊕⊝⊝ **low**^1,2^**Stool Volume**‐‐**ROM 1.05** (0.94 to 1.18)496 (8 studies)⊕⊕⊝⊝ **low**^1,2^**Bacteriological failure93 per 1000142 per 1000** (94 to 216)**RR 1.53** (1.01 to 2.32)672 (9 studies)⊕⊕⊝⊝ **low**^1,3^\*The basis for the **assumed risk** (eg the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **CI:** Confidence interval; **RR:** Risk ratio; **ROM**: Ratio of means.GRADE Working Group grades of evidence **High quality:** Further research is very unlikely to change our confidence in the estimate of effect. **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low quality:** We are very uncertain about the estimate.[^8]

Background {#CD008625-sec1-0002}
==========

Description of the condition {#CD008625-sec2-0001}
----------------------------

Cholera is an acute watery diarrhoea caused by the Gram‐negative bacterium *Vibrio cholera.* There are many serogroups of *V. cholerae*, of which O1 and O139 cause disease in humans. *V. cholerae* lives in aquatic environments, where it can survive for years in a free living cycle ([@CD008625-bbs2-0067]). It causes endemic disease in some countries and regions, but it has the potential to cause epidemics (affecting a large number of individuals within the population) and pandemics (occurring over a wide geographic area and affecting an exceptionally high proportion of the population). Children aged between two and 15 are at highest risk in endemic settings, while persons of all ages are affected during epidemics ([@CD008625-bbs2-0080]; [@CD008625-bbs2-0093]).

The incidence of cholera has been increasing globally since the beginning of the millennium, with a 24% increase in the number of cases reported for the years 2004 to 2008 as compared to the years 2000 to 2004 ([@CD008625-bbs2-0099]). However, the total of 190,130 cases reported in 2008 is considered to be a gross underestimate, because many endemic countries do not report cholera and this figure also excludes the estimated 500,000 to 700,000 cases labelled as acute watery diarrhoea that occur in some Asian and African countries ([@CD008625-bbs2-0099]). Today, the main affected regions worldwide are in Asia (Bangladesh, India, Thailand, Cambodia, and Vietnam) and many parts of Africa (including a recent outbreak described in Zimbabwe) ([@CD008625-bbs2-0072]; [@CD008625-bbs2-0090]; [@CD008625-bbs2-0093]; [@CD008625-bbs2-0100]).More recently, the Haiti outbreak spread cholera to the neighbouring Dominican Republic, as well as to Cuba and Mexico  ([@CD008625-bbs2-0089]; [@CD008625-bbs2-0091]).

*V. cholerae* is transmitted to humans by the fecal‐oral route, through ingestion of contaminated water or food ([@CD008625-bbs2-0103]). For example, one hypothesis suggests that *V. cholerae* was introduced into Haiti by infected Nepalese peacekeeping soldiers and that the epidemic spread of the organism was due to poor sanitation ([@CD008625-bbs2-0071]; [@CD008625-bbs2-0077]). The incubation period for cholera usually varies between eight to 72 hours, depending on the infectious dose and gastric acidity ([@CD008625-bbs2-0097]). *V. cholerae* O1 and O139 both cause clinical disease by secreting an enterotoxin with a sub‐unit structure comprising five B subunits and one A subunit ([@CD008625-bbs2-0073]; [@CD008625-bbs2-0075]). The B subunits bind the toxin to a specific receptor (GM1 ganglioside) on the surface of the intestinal mucosal cells. The A subunit is then released into the cell where it activates adenylate cyclase, causing a net increase in cyclic adenosine monophosphate, which blocks the absorption of sodium by the villous cells. This leads to secretion of chloride by the crypt cells, followed by secretion of water, resulting in watery diarrhoea. In endemic settings, about 90% of cholera cases are defined as mild to moderate and are clinically impossible to distinguish from other acute watery diarrhoeas such as those caused by enterotoxigenic *Escherichia coli* (ETEC) and rotavirus. The remaining 10% of cases are labelled as severe cholera. Mortality from cholera depends on several factors, but is generally preventable. The overall case fatality reported by the World Health Organization (WHO) in 2008 was 2.7%, ranging from 0% to 14.3% in different countries ([@CD008625-bbs2-0099]). The reported mortality in Haiti has been as high as 4.6% in some areas, but later decreased to 1% or less throughout the country ([@CD008625-bbs2-0069]).

Successful management of cholera depends on early diagnosis and prevention of dehydration, or prompt treatment of dehydration if it develops. Mild to moderate dehydration can be treated with Oral Rehydration Salts (ORS) solution, but severe dehydration usually requires intravenous (IV) fluids.

Description of the intervention {#CD008625-sec2-0002}
-------------------------------

The intervention assessed in this review is the impact of antimicrobial treatment as an adjunct to rehydration therapy. In theory, antimicrobials will not have an immediate effect, because the toxin is already bound to intestinal cells. However, they should affect the duration of the disease by reducing further production of the toxin, either by inhibiting bacterial protein synthesis (tetracyclines, macrolides) and/or by promoting bacterial cell death.

Shortening the duration of viable pathogen excretion might also lead to reduced transmission of infection to others and reduced contamination of the environment.

The WHO recommends antimicrobial therapy only in the management of severe cases, ie those who need intravenous rehydration because of severe dehydration; patients who are lethargic or floppy, unconscious, or unable to drink ORS; or are children with an absence of tears and very slow return of skin pinch ([@CD008625-bbs2-0098]). The current recommended treatment for adults is a single oral dose of doxycyline 300 mg or tetracycline 12.5 mg/kg six hourly for three days ([@CD008625-bbs2-0096]; [@CD008625-bbs2-0094]). In children under eight years of age, co‐trimoxazole, erythromycin or azithromycin are recommended ([@CD008625-bbs2-0096]).

The choice of antimicrobial agent is complicated by emerging resistance to antibiotics. Resistance to tetracycline emerged in 1979, followed by resistance to other antibiotic classes ([@CD008625-bbs2-0088]). A \'creeping\' increase in minimal inhibitory concentrations (MICs) to quinolones has been noted since the 1980s, mediated by chromosomal mutations. Tetracycline resistance, on the other hand, is plasmid mediated and thus MICs to tetracycline do not increase gradually. In endemic countries, most strains of *V. cholerae* are currently resistant to co‐trimoxazole, with variable resistance to tetracyclines, macrolides and quinolones ([@CD008625-bbs2-0082]). Thus, selection of antibiotic treatment should be directed by the results of antibiotic susceptibility testing of *V. cholerae* isolates at the onset of an outbreak.

Why it is important to do this review {#CD008625-sec2-0003}
-------------------------------------

Cholera epidemics continue to cause significant morbidity and mortality in many developing countries around the world. In October 2010, an epidemic of cholera started in Haiti and later spread to the neighbouring Dominican Republic. By October 2012, 604,635 cases and 7436 fatalities had been reported by the Haitian National Cholera Surveillance System ([@CD008625-bbs2-0069]).

Many randomized, controlled clinical trials have been conducted to evaluate the efficacy of various antimicrobial agents for treating cholera. Based on the results of these trials, there is a general consensus that antimicrobial treatment shortens the duration of diarrhoea and reduces stool volume ([@CD008625-bbs2-0093]; [@CD008625-bbs2-0094]). However, no systematic review has previously summarized the evidence to quantify the benefit of antimicrobial treatment with regard to these outcomes.

With the latest epidemic of cholera in Haiti in mind, we believe that there is place for a systematic review that would help answer the following questions: to what extent do antimicrobials shorten the course of the clinical disease, reduce stool volume and the need for IV or oral hydration; whether certain antimicrobials or classes of antimicrobial are more effective than others at treating cholera; and what is the optimal treatment schedule.

Objectives {#CD008625-sec1-0003}
==========

To quantify the benefit of antimicrobial treatment for patients with cholera.To determine whether different antimicrobials have different effects.To determine whether different lengths of treatment or dosing of antimicrobials have different effects.

Methods {#CD008625-sec1-0004}
=======

Criteria for considering studies for this review {#CD008625-sec2-0004}
------------------------------------------------

### Types of studies {#CD008625-sec3-0001}

Randomized controlled clinical trials or quasi‐randomized studies (using alternation, date of birth, patient identification number, weekday).

### Types of participants {#CD008625-sec3-0002}

Patients with diarrhoea caused by *V. cholerae* O1 or O139, regardless of their age and location of management (ie in‐hospital or ambulatory). We included trials that recruited participants with undiagnosed diarrhoea (eg watery diarrhoea) when they presented a separate analysis of those patients with proven cholera. In this case, we only extracted data for proven cholera cases.

### Types of interventions {#CD008625-sec3-0003}

Any antimicrobial treatment versus placebo/no treatment.Any antimicrobial versus a different antimicrobial.Different dosing or durations of the same antimicrobials.

We excluded antibiotics that are not in current clinical use, such as streptomycin, paromomycin, formosulphathiazole, formosulphacetamide, and sulfaguanidine.

In our analyses, we did not include treatment arms in which over 90% of the *V. cholerae* isolates were resistant to the tested antimicrobial.

### Types of outcome measures {#CD008625-sec3-0004}

#### Primary outcomes {#CD008625-sec4-0001}

Duration of diarrhoea: from the time of initiation of the study drug until the end of diarrhoea as defined in the study.Stool volume: from the time of initiation of the study drug until end of diarrhoea as defined in the study.

#### Secondary outcomes {#CD008625-sec4-0002}

All‐cause deaths (\'deaths\' thereafter) during the acute disease stage (ie before resolution of diarrhoea).Duration of fecal excretion of the pathogen.Clinical failure: defined as persistence of watery stools beyond 48 hours of initiation of the study drug. When this outcome was reported at various time points, we chose the last time point reported.Bacteriological failure: defined as isolation of *V. cholerae* from stools beyond 48 hours of initiation of the study drug. When this outcome was reported at various time points, we chose the last time point reported.Hydration requirements: defined as the total volume of IV fluid administered. If not reported, we used data on the total volume of rehydration fluid administered, and when that was not reported, we used the total volume of ORS administered.

All outcome definitions, including the time points defining the outcome (such as schedule and frequency of monitoring), were recorded.

We intended to assess unscheduled use of IV rehydration, body weight change, development of severe hypokalaemia, severe hyponatraemia and resistance development, but these outcomes were not reported in most trials.

Search methods for identification of studies {#CD008625-sec2-0005}
--------------------------------------------

A comprehensive search was conducted with the purpose of identifying all eligible trials regardless of language, year of publication, or status of publication (published in peer review journal, conference proceeding, thesis, or unpublished). The last search of all databases was conducted in November 2011 and the PubMed search was updated regularly until March 2014.

### Electronic searches {#CD008625-sec3-0005}

We used the search strategy explained in [Table 23](#CD008625-tbl-0023){ref-type="table"}. The search purposefully did not include terms related to the intervention because including the term \'antimicrobial\' would prevent the identification of trials that provided only the name of the antimicrobial without using \'antimicrobial\' as an Index or MeSH term. Listing all antimicrobial names was not possible since we were not aware of all types of antimicrobials that could have been assessed. In PubMed and EMBASE, search terms were used in combination with the search strategy for retrieving randomized controlled trials developed by The Cochrane Collaboration ([@CD008625-bbs2-0087]).Table 1Detailed search strategiesSearch setCIDG SRCENTRALPUbMed^a^EMBASE^a^LILACSAIMSCI1CholeraCholera\"Cholera\"\[MeSH\]CholeraCholera\$CholeraCholera2CholeraeCholeraeCholeraCholeraerandom\$CholeraeCholerae31 or 21 or 2Cholerae1 or 2aleator\$1 or 21 or 21 or 2 or 31 and (2 or 3)[^9]

We searched the following databases for eligible trials: Cochrane Infectious Disease Group Specialized Register (CIDG SR); the Cochrane Central Register of Controlled Trials (CENTRAL), published in The Cochrane Library; PubMed; EMBASE; African Index Medicus; LILACS; and the Science Citation Index (CSI).

We searched the following databases for unpublished or ongoing trials: metaRegister of Controlled Trials (mRCT) and the WHO International Clinical Trials Registry Platform (<http://www.who.int/ictrp/en/>) for ongoing or unpublished trials.

### Searching other resources {#CD008625-sec3-0006}

We attempted to contact key persons in agencies and organizations funding and conducting trials on the treatment of cholera via email, using our list of identified trials, and asked if they were aware of other unidentified trials. These persons and agencies included: Head of the Epidemic Control Preparedness Programme (ECPP) at the International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B); Director of the National Institute of Cholera and Enteric Diseases (NICED), Kolkata, India; the All India Institute of Medical Sciences (AIIMS), Delhi, India; the US Naval Medical Research Unit (NAMRU), Jakarta, Indonesia; the Naval Medical Research Unit 3 (NAMRU‐3), Cairo, Egypt; Epicentre, Paris, France; and the Institute Pasteur, Paris, France, and its network. We also attempted to contact people at the WHO.

References of all included trials were scanned.

We searched the proceedings of the following conferences: the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); and the Infectious Diseases Society of America (IDSA).

Data collection and analysis {#CD008625-sec2-0006}
----------------------------

### Selection of studies {#CD008625-sec3-0007}

Two reviewers independently applied inclusion and exclusion criteria, and the search results were documented in an Excel spreadsheet. Disagreements were resolved by discussion; if they could not be resolved, we attempted to contact the authors of the trial to clarify questions on its eligibility. The trials\' reports were scrutinized to ensure that multiple publications from the same trial were included only once. We recorded details of potentially relevant references that were excluded, along with the reason for their exclusion.

### Data extraction and management {#CD008625-sec3-0008}

A data extraction form in Excel was developed, piloted and finalized. Two reviewers independently extracted the data from included trials into the form. Any disagreements on extracted data were resolved by discussion. If no consensus could be reached, the trial authors were contacted to clarify the issue. In the event of missing or incomplete data, we attempted to contact one or more of the trial\'s authors for clarification.

We extracted descriptive data on the trials, the patients and infection characteristics, including the *V. cholerae* serogroup and biotype, and resistance rates of the *V. cholerae* sp. isolates to the antimicrobials tested. For dichotomous data, we extracted the number of patients with event and the number of patients assessed. For continuous outcomes, we preferentially extracted means and standard deviations. If reported differently, we converted medians to means and calculated the variance according to the methods described by [@CD008625-bbs2-0084]. Standard errors and other dispersion measures were converted to standard deviations where possible ([@CD008625-bbs2-0083]). If not reported numerically, outcomes were extracted from graphs or figures presented in the publications (by counting pixels). Studies are named by first author (abbreviated), year of publication and trial location using the abbreviations listed in [Table 24](#CD008625-tbl-0024){ref-type="table"}.Table 2Trial location abbreviationsAbbreviationCountryBGDBangaladeshCIVCote d\'IvoireINDIndiaIRNIranLKASri LankaNGANigeriaPAKPakistanPERPeruSOMSomaliaTHAThailandTURTurkey

### Assessment of risk of bias in included studies {#CD008625-sec3-0009}

Two reviewers independently assessed potential biases in included studies and extracted the data into the electronic table. We used a domain‐based evaluation as recommended by the *Cochrane Handbook for Systematic Reviews of Interventions* ([@CD008625-bbs2-0083]). Reviewers were not blinded to trial authors, the publication status or other study characteristics. Each domain was assigned a low or high risk of bias, using the definitions provided in the *Cochrane Handbook for Systematic Reviews of Interventions* ([@CD008625-bbs2-0083]). When there was insufficient information about the process, the domain was assigned an unclear risk of bias. The following domains were assessed for this review.

**Sequence generationAllocation concealmentBlinding of participants, personnel and outcome assessors:** we judged a priori that blinding will not affect the bacteriological outcomes or deaths, and thus did not attempt to explain results by this item.**Incomplete outcome data**: we assessed the number of exclusions and attrition for the primary outcomes. We classified studies as low risk of bias when all randomized patients were evaluated for a given outcome or up to 10% were missing without an explanation ([@CD008625-bbs2-0083]); we classified studies as unclear risk of bias when the number of randomized patients was unknown; all other studies were classified as high risk unless the reasons for attrition were provided and valid.**Selective outcome reporting:** we assessed this domain by comparing protocol‐defined outcomes with those reported. When the protocol was unavailable, we compared outcome definitions in the methods with those reported in the results. When the study reported on the outcomes specified, it was classified as low risk; if outcomes were not defined in the protocol/methods or reported outcomes were not specified in the protocol/methods, the study was classified as high‐risk; and when the outcome was poorly defined in the protocol/methods (e.g. no time point), we classified the study as unclear risk. We created a matrix of studies and outcomes ([@CD008625-bbs2-0083]).**Other biases:** early stop of the trial or one or more of its arms.

Disagreements regarding extracted data were resolved through discussion. If no consensus could be reached, we contacted the trial authors to clarify the issues. In the event of missing or incomplete data, we contacted one of the trial\'s authors and asked for the missing data.

### Measures of treatment effect {#CD008625-sec3-0010}

For dichotomous data, we compared study groups using risk ratios (RRs). For continuous outcomes, we calculated absolute mean differences (MDs) when the units of analysis were uniform. For outcomes dependent on weight that were described in litres or mL/kg (for example, stool volume, hydration requirements), we computed the ratio of arithmetic means (ROM, [@CD008625-bbs2-0078]; [@CD008625-bbs2-0079]). All effect measures are reported with 95% confidence intervals (CIs).

### Unit of analysis issues {#CD008625-sec3-0011}

When the same trial was included in a single meta‐analysis more than once (because it had multiple intervention groups), we divided the number of events and participants in the placebo arm for dichotomous outcomes and we divided the number of participants for continuous outcomes ([@CD008625-bbs2-0083]).

### Dealing with missing data {#CD008625-sec3-0012}

We tried to complement all missing data by correspondence with trial authors (via email). In case of missing data, we performed a complete case analysis for all outcomes and recorded the number of dropouts.

### Assessment of heterogeneity {#CD008625-sec3-0013}

We visually inspected the forest plots before performing statistical tests. Heterogeneity in each meta‐analysis was assessed using a Chi^2^ test of heterogeneity, with a P value [\<]{.ul} 0.10 used to indicate statistical significance, and using the I^2^ test of inconsistency, with a value [\>]{.ul} 50% indicating substantial inconsistency. The importance of the observed I^2^ value was interpreted in terms of the magnitude and direction of the effects.

### Assessment of reporting biases {#CD008625-sec3-0014}

In analyses that included more than 10 trials, we planned to construct funnel plots of effect estimates against study precision. Asymmetry was inspected visually to determine publication bias or other small study effects.

### Data synthesis {#CD008625-sec3-0015}

We created an antimicrobial treatment network based on antimicrobial class, as previously described ([@CD008625-bbs2-0086]). We visually inspected the treatment network to identify missing comparisons. The following comparisons were conducted:

any antimicrobial versus placebo/no treatment, subcategorized by the antimicrobial;direct comparisons between different antimicrobials or antimicrobial classes;indirect comparisons between antimicrobials;short versus longer duration of treatment with the same antimicrobial class, considering the effective antimicrobial treatment duration (related the duration of administration and the antibiotic\'s half‐life);low versus high doses of the same antimicrobial.

We pooled results without significant heterogeneity using the Mantel‐Haenzel fixed‐effect model. When significant heterogeneity was present and it was still appropriate to pool results, we used a random‐effects model. For dichotomous outcomes with zero events reported in both arms of a trial, we conducted a meta‐analysis of risk differences. ROMs were pooled using the inverse variance method on a log scale.

Indirect comparisons were performed using the methods described by [@CD008625-bbs2-0070] and existing recommendations for reporting of indirect comparisons ([@CD008625-bbs2-0074]). Briefly, for continuous outcomes the mean difference for A versus B equalled : mean difference A versus placebo ‐ mean difference B versus placebo; and variance C versus B equalled: variance A versus placebo + variance B versus placebo. For dichotomous outcomes, log (risk ratio of A versus B) equalled: log(risk ratio of P (control)  versus B (treatment)) ‐ log(risk ratio of P (control)  versus A (treatment)); and SE (log risk ratio A versus B) equalled: square root (standard error of the log risk ratio of P versus B + standard error of the log risk ratio of P versus A).

Analyses were performed using Review Manager 5 ([@CD008625-bbs2-0092]). Two authors working independently checked data entered into Review Manager 5.

### Subgroup analysis and investigation of heterogeneity {#CD008625-sec3-0016}

We primarily investigated heterogeneity by sub‐grouping all analyses by the type of antibiotic used. We then also examined the following subgroups.

Age of participants: children or adults.*V. cholerae* serogroup: O1 versus O139. (If serogroup was not reported, we assumed that all *V. cholerae* strains in studies conducted before 1992 belonged to the O1 serogroup. Studies in which over 75% of all isolates were O1 were also included in the O1 subgroup.)Dehydration severity at baseline: trials recruiting only participants with severe dehydration vs those with variable inclusion (for clinical outcomes only).   Timing of stool volume examination: separating studies in which continuous outcomes were monitored in exact time intervals of six or eight hours versus those with a vague time definition.

### Sensitivity analysis {#CD008625-sec3-0017}

We assessed the effect of allocation concealment on outcomes.We restricted the analysis to trials reporting means and standard deviations, excluding means that were estimated from medians.

#### Assessment of the quality of evidence {#CD008625-sec4-0003}

We assessed the quality of evidence across each outcome measure using the GRADE approach. The quality rating across trials has four levels: high, moderate, low, or very low. RCTs are initially categorized as high quality but can be downgraded after assessment of five criteria: risk of bias, consistency, directness, imprecision, and publication bias ([@CD008625-bbs2-0081]). As part of the assessment of precision we performed sample size calculations for each outcome to determine if the trials or the meta‐analysis were adequately powered to confidently detect or exclude clinically important effects (see [Table 25](#CD008625-tbl-0025){ref-type="table"}; [Table 26](#CD008625-tbl-0026){ref-type="table"}).Table 3Optimal Information Size Calculations: Continuous outcomes**OutcomeHypothesisPowerα errorMean in control groupMean in intervention groupStandard deviationTotal sample size requiredDiarrhoea duration**Superiority80%5%30^1^15101430^1^221050130^1^654012130^1^984050**Duration of pathogen excretion**Superiority80%5%3^2^1.51203^2^2.251766^2^32206^2^4.5276[^10]Table 4Optimal Information Size Calculations: Dichotomous outcomes**OutcomeHypothesisPowerα errorProportion in control groupProportion intervention groupTotal sample size requiredClinical failure**Superiority80%5%60%^1^30%^3^8060%45%^4^34212%^2^6%^3^70812%9%^4^3272**Bacteriological failure**Superiority80%5%75%37.5%^3^4875%56.25%^4^19420%10%^3^39420%15%^4^1806[^11]

Results {#CD008625-sec1-0005}
=======

Description of studies {#CD008625-sec2-0007}
----------------------

### Results of the search {#CD008625-sec3-0018}

Our search yielded a large number of references: 65 were deemed relevant and the full text of 64 could be retrieved. Twenty‐three studies were excluded for reasons specified in [Characteristics of excluded studies](#CD008625-sec2-0018){ref-type="sec"}. We were unable to obtain one article ([@CD008625-bbs2-0063]) and three ongoing studies were identified (see the [Characteristics of ongoing studies](#CD008625-sec2-0020){ref-type="sec"} table).

### Included studies {#CD008625-sec3-0019}

Thirty‐nine different trials are included in this review, described in 41 publications. The trials were conducted between 1964 and 2007, and published between 1964 and 2010. The trials were predominantly conducted in Bangladesh, India and Pakistan (15, 10, and three trials, respectively), with additional trials in Thailand (2), Sri Lanka (1), Somalia (1), Nigeria (1), Ivory Coast (1), Peru (2), Turkey (1), Iran (1), and one multi‐centre trial (Thailand, Indonesia, Ivory Coast, Mexico, Israel, and Italy).

Twelve trials were conducted during an epidemic of cholera and the remaining were conducted in endemic settings. Most trials were multi‐armed: 16 trials included four or more study arms, rendering a large number of different comparisons. We created a treatment network showing the various comparisons and the number of trials examining each comparison ([Figure 1](#CD008625-fig-0001){ref-type="fig"}). All the antimicrobials in [Figure 1](#CD008625-fig-0001){ref-type="fig"}, except for azithromycin, were compared to placebo/no treatment (comparisons not shown in [Figure 1](#CD008625-fig-0001){ref-type="fig"}).Figure 1An antimicrobial treatment network based on antimicrobial drug or class. This figure describes the different comparisons in all included studies which compared one antimicrobial vs another antimicrobial (comparisons vs. placebo/ no treatment not included).

#### Participant characteristics {#CD008625-sec4-0004}

A total of 4623 patients took part in the trials, with a median of 77 participants per trial (range 20 to 450). Nine of the trials included only children, 23 included only adults and the remaining seven included both. Seventeen trials excluded girls/ women, because of the difficulty separating stool from urine without a catheter, and seven further trials did not report on the sex of the study participants. The case definition in most trials specified a history of acute watery diarrhoea, lasting 24 hours or less. However, all trials included in their final analysis only patients with bacteriologically‐proven cholera. Twenty‐seven trials (70%) included some measure of severity in their case definition (eg low blood pressure, severe dehydration) and six trials excluded patients with severe cholera. Twenty‐eight studies reported exclusion of patients who had received antimicrobial therapy prior to enrolment, two trials allowed inclusion of such patients, and the remaining did not refer to previous antimicrobial treatment.

#### Infection characteristics {#CD008625-sec4-0005}

The isolated *V. cholerae* strains belonged to serogroup O1 in 23 studies, serogroup O139 in three studies, and both serogroups in six studies, while the *V. cholerae* serogroup was not reported in the remaining studies. We assumed that the strains in studies conducted before 1992 (four studies) belonged to serogroup O1, as this was the year in which serogroup O139 first emerged \[[@CD008625-bbs2-0085]\]. Identification of *V. cholerae* was made by culture in 12 studies (the earliest conducted in 1963 and the latest in 1996) and by dark field microscopy in 15 (the earliest published in 1971 and the latest conducted in 2002); the remaining publications did not describe the methods of laboratory confirmation.

Nineteen studies reported that all isolates were susceptible to the study drugs, while 13 studies did not report susceptibility data. The remaining seven studies reported various degrees of resistance to several different antimicrobials:

Tetracycline resistance: [@CD008625-bbs2-0013] (7%); [@CD008625-bbs2-0020] (100%); [@CD008625-bbs2-0030] (13.3%); [@CD008625-bbs2-0033] (24%)Cotrimoxazole: [@CD008625-bbs2-0016] (23%)Erythromycin: [@CD008625-bbs2-0002] (100%); [@CD008625-bbs2-0016] (23%)Furazolidone: [@CD008625-bbs2-0030] (22.2%); [@CD008625-bbs2-0031] (10%).

We excluded study arms with 100% resistance from the meta‐analysis.

### Excluded studies {#CD008625-sec3-0020}

Most excluded studies were non‐randomized (see [Characteristics of excluded studies](#CD008625-sec2-0018){ref-type="sec"}). Two studies conducted by the same group were declared randomized, but the randomization methods were not described and differences between groups at baseline suggested a lack of adequate randomization ( [@CD008625-bbs2-0048]; [@CD008625-bbs2-0047]). We could not establish contact with the authors and these trials were excluded. We excluded a four‐armed pseudo‐randomized trial (using alternation) conducted in 1950, which assessed sulphaguanidine, formosulphathiazole, and formosulphacetamide against no treatment ([@CD008625-bbs2-0046]). These antimicrobials are no longer used in humans and the mortality in this trial was higher in the antimicrobial arms (30 to 34%) than in the no treatment arm (18%). Finally, we excluded a trial conducted in 1964 in the Philippines ([@CD008625-bbs2-0056]), which was a pseudo‐randomized trial (using alternation) comparing sulphaguanidine versus no treatment.

Risk of bias in included studies {#CD008625-sec2-0008}
--------------------------------

A visual summary of the risk of bias assessment can be seen in [Figure 2](#CD008625-fig-0002){ref-type="fig"} and [Figure 3](#CD008625-fig-0003){ref-type="fig"}.Figure 2Risk of bias graph: review authors\' judgements about each risk of bias item presented as percentages across all included studies.Figure 3Risk of bias summary: review authors\' judgements about each risk of bias item for each included study.

### Allocation {#CD008625-sec3-0021}

Nineteen studies described an adequate method for generating a random allocation sequence. Five studies used alternate allocation based on the order of arrival at hospital and were considered to be at high risk of selection bias ([@CD008625-bbs2-0006]; [@CD008625-bbs2-0017]; [@CD008625-bbs2-0024]; [@CD008625-bbs2-0025]; [@CD008625-bbs2-0032]). The remaining trials did not describe their methods of randomization and so are at unclear risk. 

Fourteen studies described an adequate method for concealing allocation and were judged to be at low risk of bias, and 20 studies did not describe allocation concealment and so are at unclear risk of bias.

### Blinding {#CD008625-sec3-0022}

Sixteen trials were double blinded, while in two trials the outcome assessor alone was blinded. The remaining 21 trials were open‐labelled.

### Incomplete outcome data {#CD008625-sec3-0023}

We examined incomplete outcome data reporting for the two primary outcomes. Out of 30 trials reporting on diarrhoea duration, nine were classified as low risk, 11 as high risk and the remainder were classified as unclear risk of incomplete outcome because the number of randomized patients was not explicitly stated. Out of 29 trials reporting on stool volume, 13 were low risk, eight were high risk and the remainder were unclear.

### Selective reporting {#CD008625-sec3-0024}

Study protocols were not available. The primary outcome was not defined in the methods section in eight (20.5%) of the publications. In most publications (26 out of 39, 66.7%), the primary outcomes were defined without specifying the time point for assessment, while the primary outcomes were fully defined in five publications. When primary outcomes were defined, 13 studies defined a single primary outcome, six studies defined more than one outcome and 12 studies included all outcomes as \'primary\'. Primary and secondary outcomes defined in the methods were reported in the results quantitatively in all publications. The outcome matrix showed that out of the 39 included studies, the number of studies reporting review‐defined outcomes were as follows:

diarrhoea duration: 29volume of diarrhoea: 29deaths: 14duration of pathogen excretion: 16microbiological failure: 31clinical failure: 18volume of rehydration fluids (IV or orally): 24.

### Other potential sources of bias {#CD008625-sec3-0025}

Eight trials were sponsored by a pharmaceutical company that manufactured one of the study drugs; another six received only the study drug from the company. Fourteen studies were under academic sponsorship, and the remaining 11 publications did not specify whether the trial was sponsored or not. Approval of an ethics committee was reported in 10 trials (24%) and informed consent was reported in 22 trials (54%).

Effects of interventions {#CD008625-sec2-0009}
------------------------

See: [Table 1](#CD008625-tbl-0001){ref-type="table"}; [Table 2](#CD008625-tbl-0002){ref-type="table"}; [Table 3](#CD008625-tbl-0003){ref-type="table"}; [Table 4](#CD008625-tbl-0004){ref-type="table"}; [Table 5](#CD008625-tbl-0005){ref-type="table"}; [Table 6](#CD008625-tbl-0006){ref-type="table"}; [Table 7](#CD008625-tbl-0007){ref-type="table"}

### Section 1. Antimicrobials versus placebo/ no treatment {#CD008625-sec3-0026}

A total of 23 trials included a comparison of antimicrobials versus placebo/no treatment, contributing to one or more of the outcomes detailed below. The last trial was completed in 1994. 

#### Primary analysis {#CD008625-sec4-0006}

##### Diarrhoea duration {#CD008625-sec5-0001}

On average, antimicrobials reduced the duration of diarrhoea by about one and a half days compared to placebo or no treatment (MD ‐36.77 hours, 95% CI ‐43.51 to ‐30.03, 18 trials, 1479 participants, [Analysis 1.1](#CD008625-fig-00101){ref-type="fig"}). However, there were statistically significant subgroup differences in the magnitude of the effect (P \< 0.00001). Tetracycline, the most studied antibiotic, shortened the duration of diarrhoea by almost two days (MD ‐47.38 hours, 95% CI ‐52.36 to ‐42.41, I^2^ = 0%, 11 trials, 665 participants); doxycycline shortened the duration by just over one day (MD ‐25.44 hours, 95% CI ‐38.90 to ‐11.99, I^2^ = 50%, three trials, 91 participants); and norfloxacin shortened the duration by less than half a day (MD ‐10.80 hours, 95% CI ‐14.13 to ‐7.48, I² = 0%, three trials, 123 participants).

##### Stool volume {#CD008625-sec5-0002}

Thirteen trials reported stool volume as total litres excreted, while four studies reported it as mL/kg body weight. The results were highly skewed in most trials.

Overall, the mean stool volume was 50% lower in those treated with antibiotics compared to placebo/no treatment (ROM 0.50, 95% CI 0.45 to 0.56, 17 trials, 1716 participants, [Analysis 1.2](#CD008625-fig-00102){ref-type="fig"}).  As with diarrhoea duration, there were statistically significant sub‐group differences between antibiotics (P = 0.01). Tetracycline was again the most studied antibiotic and reduced stool volume by 56% (ROM 0.44, 95% CI 0.39 to 0.50, I^2^ =0%, 12 trials, 771 participants). Large effects were also seen with norfloxacin (two trials), ciprofloxacin (one trial), doxycycline (three trials), chloramphenicol (three trials), furazolidone (five trials), and ampicillin (one trial).

##### Deaths {#CD008625-sec5-0003}

No deaths were reported in all trials, although only six trials explicitly stated that no deaths occurred ([Analysis 1.3](#CD008625-fig-00103){ref-type="fig"}).

##### Clinical failure {#CD008625-sec5-0004}

Clinical failure was variably assessed between 48 to 96 hours after enrolment to the study or from starting to take the study drugs.

Overall, clinical failure was significantly lower with antimicrobial treatment (RR 0.21, 95% CI 0.13 to 0.34, 10 trials, 1023 patients, [Analysis 1.4](#CD008625-fig-00104){ref-type="fig"}). Tetracycline reduced the risk of clinical failure by 90% (RR 0.10, 95% CI 0.05 to 0.22, I^2^ = 46%, six trials, 431 participants), and statistically significant effects were also seen with fleroxacin (one trial), trimethoprim‐sulfamethoxazole (TMP‐SMX; two trials), chloramphenicol (two trials), and sulfometoxine (one trial).

##### Hydration requirements {#CD008625-sec5-0005}

Eight trials reported total hydration fluid requirement as litres, while three trials reported it as mL/kg body weight.

Overall, the total volume of hydration fluid required was 40% lower in patients given antibiotics (ROM 0.60, 95% CI 0.53 to 0.68, 11 trials, 1201 participants, [Analysis 1.5](#CD008625-fig-00105){ref-type="fig"}). The effect was slightly greater than the pooled total with tetracycline (ROM 0.50, 95% CI 0.43 to 0.58, I^2^ =19%, eight trials, 604 participants), and lower for doxycycline (ROM 0.76, 95% CI 0.57 to 1.02, I^2^ = 37%, two trials, 66 participants) and norfloxacin (ROM 0.72, 95% CI 0.60 to 0.86, I^2^ = 57%, two trials, 98 participants ). Beneficial effects were also seen with chloramphenicol (two trials) and amoxicillin (one trial). 

##### Pathogen excretion duration {#CD008625-sec5-0006}

The mean duration of pathogen excretion was significantly shorter in patients given antibiotics (MD ‐2.74 days, 95% CI ‐3.07 to ‐2.40, 11 trials, 1009 participants, [Analysis 1.6](#CD008625-fig-00106){ref-type="fig"}). Tetracycline was the most studied antibiotic and reduced the duration of excretion by three days (MD ‐3.05 days, 95% CI ‐3.43 to ‐2.67, I^2^ = 60%, 11 trials, 616 participants). Large beneficial effects were also seen with TMP‐SMX (one trial), chloramphenicol (two trials), and furazolamide (three trials). All studies monitored stools for pathogen excretion daily.

##### Bacteriological failure {#CD008625-sec5-0007}

As for clinical failure, microbiological failure was variably assessed at 48 to 96 hours after enrolment to study or from start of the study drugs.

Overall, bacteriological failure was significantly lower with antimicrobial therapy (RR 0.25, 95% CI 0.16 to 0.39, 15 trials, 1147 patients, [Analysis 1.7](#CD008625-fig-00107){ref-type="fig"}), but with significant subgroup differences (P \< 0.00001) and significant heterogeneity within some subgroups. Considerable heterogeneity was present in the analysis of tetracycline, but all studies pointed in the same direction (RR 0.28, 95% CI 0.13 to 0.64, I^2^ = 86%, seven trials, 320 participants), with large reductions seen in small trials of doxycycline (two trials), norfloxacin (three trials), fleroxacin (one trial), ciprofloxacin (one trial), and erythromycin (three trials).

#### Sensitivity analysis  {#CD008625-sec4-0007}

##### Risk of bias {#CD008625-sec5-0008}

We evaluated the possible influence of poor study design on the observed effects of antimicrobial treatment by conducting a sensitivity analysis against the risk of selection bias. For duration of diarrhoea ([Analysis 2.1](#CD008625-fig-00201){ref-type="fig"}), stool volume ([Analysis 2.2](#CD008625-fig-00202){ref-type="fig"}), hydration requirements ([Analysis 2.4](#CD008625-fig-00204){ref-type="fig"}), clinical failure ([Analysis 2.3](#CD008625-fig-00203){ref-type="fig"}), and bacteriological failure ([Analysis 2.6](#CD008625-fig-00206){ref-type="fig"}), the largest effects were observed in trials at high risk of selection bias and the smallest effects in trials at low risk of bias. Nevertheless, when the analysis was restricted to those to studies at low risk of bias, the benefits of antibiotics remained both statistically and clinically significant.

##### Conversion of medians to means {#CD008625-sec5-0009}

When excluding trials reporting results in medians (which we converted into means), the results remained almost identical to the main analysis (data not shown).

##### Time definition {#CD008625-sec5-0010}

For stool volume, the time interval for stool output assessment was eight hours in 16 studies, six hours in six studies, 24 hours or more in four studies, and not reported in 13 studies. Heterogeneity dropped significantly in the group of trials with exact time intervals of eight hours (MD ‐42.21 hours, 95% CI ‐47.64 to ‐36.78, I² = 45%, nine trials, 1038  patients, [Analysis 3.1](#CD008625-fig-00301){ref-type="fig"}).

For clinical and bacteriological failure, there were no significant differences in effects between trials assessing failure at 48, 72 or 96 hours ([Analysis 3.2](#CD008625-fig-00302){ref-type="fig"}; [Analysis 3.3](#CD008625-fig-00303){ref-type="fig"}).

#### Subgroup analysis {#CD008625-sec4-0008}

##### Age of participants {#CD008625-sec5-0011}

No statistically significant subgroup differences were seen (data not shown).

##### Cholera serogroups {#CD008625-sec5-0012}

No statistically significant subgroup differences were seen (data not shown).

##### Level of dehydration at baseline {#CD008625-sec5-0013}

The effect of antimicrobials was smaller in trials where all patients were severely dehydrated at baseline compared to studies with broader inclusion criteria (range 0 to 88% severely dehydrated) for duration of diarrhoea (test for subgroup differences P = 0.005, [Analysis 4.1](#CD008625-fig-00401){ref-type="fig"}), stool volume (P = 0.07, [Analysis 4.2](#CD008625-fig-00402){ref-type="fig"}), and hydration requirements (P = 0.04, [Analysis 4.4](#CD008625-fig-00404){ref-type="fig"}). There were no subgroup differences for clinical failure (P = 0.77, [Analysis 4.3](#CD008625-fig-00403){ref-type="fig"}).

##### Antimicrobial resistance {#CD008625-sec5-0014}

Restriction of the analysis of bacteriological failure to studies reporting that all cholera isolates were susceptible to the administered antimicrobials resulted in similar results to the overall analysis (RR of 0.13, 95% CI 0.06 to 0.27, [Analysis 5.1](#CD008625-fig-00501){ref-type="fig"}).

#### Small study effects {#CD008625-sec4-0009}

The funnel plots for most outcomes in the comparison of antimicrobial versus placebo/no treatment did not show a small study effect; only in the clinical and microbiological failure analyses did small studies tend to show a larger effect, but these analyses included only a small proportion of existing studies.

#### Assessment of quality of evidence {#CD008625-sec4-0010}

This comparison is summarized in [Table 1](#CD008625-tbl-0001){ref-type="table"}. The evidence for the large effect of antibiotics on the duration of diarrhoea, total stool volume, fluid requirement, and pathogen excretion duration was judged to be of moderate quality, meaning we have reasonable confidence in these results. We downgraded the quality of evidence from high to moderate because the effects appear to be exaggerated in trials at high risk of selection bias. We did not downgrade for inconsistency, as much of the observed heterogeneity was explained by differences between antibiotic classes and differences in the timing of outcome measurements. We also did not downgrade for indirectness despite many of the trials being old. We consider the observed effects applicable to effective antibiotics today.

### Section 2. Comparison between different antimicrobials {#CD008625-sec3-0027}

Direct comparisons are addressed, followed by indirect comparisons where relevant. Funnel plots were not drawn for all head‐to‐head comparisons because of the paucity of trials in most comparisons.

#### Azithromycin versus ciprofloxacin {#CD008625-sec4-0011}

Two trials have directly compared single doses of azithromycin (effective duration of four days) and ciprofloxacin (effective duration of 12 hours) among children ([@CD008625-bbs2-0018]) and adults ([@CD008625-bbs2-0036]).

Compared to ciprofloxacin, treatment with azithromycin reduced the mean duration of diarrhoea by over a day (MD ‐32.43 hours, 95% CI ‐62.90 to ‐1.95, two trials, 375 participants, [Analysis 6.1](#CD008625-fig-00601){ref-type="fig"}), reduced stool volume by about two‐thirds (ROM 0.35, 95% CI 0.28 to 0.44, one trial, 195 participants, [Analysis 6.2](#CD008625-fig-00602){ref-type="fig"}), reduced hydration requirements by about a third (ROM 0.66, 95% CI 0.52 to 0.83, two trials, 375 participants, [Analysis 6.3](#CD008625-fig-00603){ref-type="fig"}), and reduced bacteriological failure at 48 to 72 hours by over three‐quarters (RR 0.23, 95% CI 0.16 to 0.34, two trials, 375 participants, [Analysis 6.5](#CD008625-fig-00605){ref-type="fig"}).

This comparison is summarized in [Table 2](#CD008625-tbl-0002){ref-type="table"}. The quality of the evidence for a reduction in diarrhoea duration was judged to be moderate. We downgraded the evidence because the trial that demonstrated the largest effect had baseline imbalances favouring azithromycin ([@CD008625-bbs2-0036]). The effects on stool volume and bacteriological failure were further downgraded to low quality due to concerns about indirectness and inconsistency, respectively.

#### Azithromycin versus erythromycin {#CD008625-sec4-0012}

One trial directly compared single dose azithromycin (effective duration of four days) with three days of erythromycin ([@CD008625-bbs2-0022]), and one trial compared a three‐day regimen of both drugs ([@CD008625-bbs2-0003]).

Compared to erythromycin, azithromycin reduced the duration of diarrhoea by half a day (MD 12.05 hours, 95% CI ‐22.02 to ‐2.08, two trials, 179 participants, [Analysis 7.1](#CD008625-fig-00701){ref-type="fig"}), and reduced the total stool volume by a third (ROM 0.69, 95% CI 0.56 to 0.85, two trials, 172 participants, [Analysis 7.2](#CD008625-fig-00702){ref-type="fig"}). Hydration requirements were lower with azithromycin, but this did not reach statistical significance (two trials, 172 participants, [Analysis 7.3](#CD008625-fig-00703){ref-type="fig"}), and no differences were observed for clinical failure ([Analysis 7.4](#CD008625-fig-00704){ref-type="fig"}) or bacteriological failure ([Analysis 7.5](#CD008625-fig-00705){ref-type="fig"}).

This comparison is summarized in [Table 3](#CD008625-tbl-0003){ref-type="table"}. The quality of evidence for the reduction in diarrhoea duration and stool volume was judged to be of moderate quality.

#### Tetracycline versus doxycycline {#CD008625-sec4-0013}

Three trials directly compared tetracycline with doxycycline. In two trials tetracycline was given four times daily for four days ([@CD008625-bbs2-0008]; [@CD008625-bbs2-0032]), and in one trial tetracycline was given four times daily for two days ([@CD008625-bbs2-0001]). All trials administered a total dose of 300 mg of doxycycline, spread over three days ([@CD008625-bbs2-0032]), two days ([@CD008625-bbs2-0008]) or given as a single dose ([@CD008625-bbs2-0001]).

Overall, no consistent clinically important differences were observed for diarrhoea duration, stool volume, or hydration requirements (three trials, 230 participants, [Analysis 8.1](#CD008625-fig-00801){ref-type="fig"}; [Analysis 8.2](#CD008625-fig-00802){ref-type="fig"},[Analysis 8.4](#CD008625-fig-00804){ref-type="fig"}), or for duration of pathogen excretion (two trials, 66 participants, [Analysis 8.5](#CD008625-fig-00805){ref-type="fig"}). Only a few patients with bacteriological failure were reported, but this reached statistical significance in favour of tetracycline (RR 0.20, 95% CI 0.06 to 0.68, two trials, 198 participants, [Analysis 8.6](#CD008625-fig-00806){ref-type="fig"}).

This comparison is summarized in [Table 4](#CD008625-tbl-0004){ref-type="table"}. The evidence of no difference between antimicrobials was downgraded to low quality due to concerns about the risk of bias of the studies and their age, with the most recent study being 25 years old.

This direct evidence is in contrast to the indirect evidence comparing tetracycline (10 trials) and doxycycline (three trials) with placebo/no treatment. In this analysis, diarrhoea duration was almost a day shorter in the trials using tetracycline compared with the trials using doxycycline (MD 21.94 hours, 95% CI ‐36.29 to ‐7.59, [Analysis 1.1](#CD008625-fig-00101){ref-type="fig"}), while the stool volume reduction was significantly higher with tetracycline (ROM 0.44, 95% CI 0.39 to 0.50) compared to doxycycline (ROM 0.64, 95% CI 0.51 to 0.81, [Analysis 1.2](#CD008625-fig-00102){ref-type="fig"}, P = 0.004 for subgroup difference).

#### Tetracycline versus quinolones {#CD008625-sec4-0014}

Three trials compared tetracycline with quinolones. The three trials compared tetracycline 500 mg four times daily for three days with: ciprofloxacin 1 g single dose ([@CD008625-bbs2-0019]); ciprofloxacin 250 mg once daily for three days ([@CD008625-bbs2-0012]); and norfloxacin 400 mg twice daily for three days ([@CD008625-bbs2-0028]).

There were no statistically significant differences in the duration of diarrhoea (three trials, 259 participants, [Analysis 9.1](#CD008625-fig-00901){ref-type="fig"}), stool volume (two trials, 234 participants, [Analysis 9.2](#CD008625-fig-00902){ref-type="fig"}), clinical failure (one trial, 202 participants, [Analysis 9.4](#CD008625-fig-00904){ref-type="fig"}), hydration requirements (two trials, 234 participants, [Analysis 9.5](#CD008625-fig-00905){ref-type="fig"}), duration of pathogen excretion (one trial, 25 participants, [Analysis 9.6](#CD008625-fig-00906){ref-type="fig"}), or bacteriological failure (two trials, 234 participants, [Analysis 9.7](#CD008625-fig-00907){ref-type="fig"}).

This evidence of no difference was judged to be of low to moderate quality (see [Table 5](#CD008625-tbl-0005){ref-type="table"}).

In indirect comparisons, tetracycline appeared to have a larger effect on diarrhoea duration than norfloxacin, compared to placebo/no treatment (P \< 0.002 for subgroup difference, [Analysis 1.1](#CD008625-fig-00101){ref-type="fig"}). Statsitically significant subgroup differences in favour of tetracycline were also seen for stool volume (P=0.004, [Analysis 1.2](#CD008625-fig-00102){ref-type="fig"}) and hydration requirements (P=0.003, [Analysis 1.5](#CD008625-fig-00105){ref-type="fig"}).

#### Tetracycline versus TMP‐SMX {#CD008625-sec4-0015}

Three trials compared tetracycline (500 mg four times daily for three days) versus TMP‐SMX (twice daily for three days) ([@CD008625-bbs2-0010]; [@CD008625-bbs2-0011]; [@CD008625-bbs2-0013]).

Compared to TMP‐SMX, diarrhoea duration was slightly shorter in those treated with tetracycline (MD ‐6.44 hours, 95% CI ‐10.93 to ‐1.96, two trials, 152 participants, [Analysis 10.1](#CD008625-fig-01001){ref-type="fig"}); stool volume was not reported. Clinical failure was also lower with tetracycline (RR 0.56, 95% CI 0.34 to 0.92, two trials, 152 participants, [Analysis 10.2](#CD008625-fig-01002){ref-type="fig"}). In one small trial, pathogen excretion was reduced by a day with tetracycline (MD ‐1.1 days, 95% CI ‐1.74 to ‐0.46, one trial, 45 participants, [Analysis 10.3](#CD008625-fig-01003){ref-type="fig"}), but there was no difference in bacteriological failure across all three trials (three trials, 173 participants, [Analysis 10.4](#CD008625-fig-01004){ref-type="fig"}).

In indirect comparisons, tetracycline was associated with a greater reduction in diarrhoea duration (MD ‐47.38 hours tetracycline vs ‐30.76 hours TMP‐SMX, test for subgroup differences P=0.09, [Analysis 1.1](#CD008625-fig-00101){ref-type="fig"}) and a greater reduction in clinical failure (RR 0.10 tetracycline vs 0.33 TMP‐SMX, test for subgroup differences P = 0.02 , [Analysis 1.4](#CD008625-fig-00104){ref-type="fig"}).

#### Tetracycline versus other antibiotics {#CD008625-sec4-0016}

Tetracycline has also been directly compared to: chloramphenicol (three trials); furazolidone (four trials); ampicillin (two trials); erythromycin (two trials); and sulphadoxine (two trials).

Tetracycline was more effective than chloramphenicol for all outcomes examined, without statistically significant differences ([Analysis 11.1](#CD008625-fig-01101){ref-type="fig"}; [Analysis 11.2](#CD008625-fig-01102){ref-type="fig"}; [Analysis 11.4](#CD008625-fig-01104){ref-type="fig"}; [Analysis 11.3](#CD008625-fig-01103){ref-type="fig"}), except for pathogen excretion duration where the difference of about one day was statistically significant ([Analysis 11.5](#CD008625-fig-01105){ref-type="fig"}).

Tetracycline was also more effective than furazolidone for most outcomes examined, with these differences statistically significant for diarrhoea duration (mean difference ‐16.00 hours, 95% CI ‐31.26 to ‐0.74, [Analysis 12.1](#CD008625-fig-01201){ref-type="fig"}), stool volume ([Analysis 12.2](#CD008625-fig-01202){ref-type="fig"}), hydration requirements ([Analysis 12.5](#CD008625-fig-01205){ref-type="fig"}), and clinical failure ([Analysis 12.4](#CD008625-fig-01204){ref-type="fig"}). There was no difference in deaths ([Analysis 12.3](#CD008625-fig-01203){ref-type="fig"}).

For the remaining comparisons (versus ampicillin, erythromycin and sulphadoxine), diarrhoea duration was not reported. Consistent clinical differences were not detected (data not shown), except for an advantage of tetracycline in hydration requirements in comparison to ampicillin or erythromycin (ROM 0.43, 95% CI 0.25 to 0.73, [@CD008625-bbs2-0033]) and in bacteriological failure in comparison to sulphadoxine (RR 0.14, 95% CI 0.02 to 0.96, [@CD008625-bbs2-0027]).

#### Doxycycline versus quinolones {#CD008625-sec4-0017}

Four trials were included overall, with three of the trials having a similar treatment duration (single dose) ([@CD008625-bbs2-0009]; [@CD008625-bbs2-0019]; [@CD008625-bbs2-0021]) and one trial having a longer duration ([@CD008625-bbs2-0037]). Ciprofloxacin was examined in three trials and norfloxacin in one trial ([@CD008625-bbs2-0009]).

There was no clinically or statistically significant difference in diarrhoea duration ([Analysis 13.1](#CD008625-fig-01301){ref-type="fig"}), stool volume ([Analysis 13.2](#CD008625-fig-01302){ref-type="fig"}) or deaths ([Analysis 13.3](#CD008625-fig-01303){ref-type="fig"}). Hydration requirements were lower with quinolones, although there was only a small magnitude of effect based mostly on the results of a single trial ([Analysis 13.4](#CD008625-fig-01304){ref-type="fig"}). Bacteriological failure occurred more frequently with doxycycline (RR 5.84, 95% CI 2.70 to 12.65, [Analysis 13.5](#CD008625-fig-01305){ref-type="fig"}).

The quality of the evidence was rated low to moderate for the main outcomes ([Table 6](#CD008625-tbl-0006){ref-type="table"}).

For indirect comparisons, no differences between doxycycline and quinolones were observed.

#### Erythromycin versus ciprofloxacin {#CD008625-sec4-0018}

Three trials compared erythromycin with ciprofloxacin ([@CD008625-bbs2-0019]; [@CD008625-bbs2-0020]; [@CD008625-bbs2-0035]) and found no statistically significant differences (data not shown). 

#### TMP‐SMX versus other antibiotics {#CD008625-sec4-0019}

Two trials compared TMP‐SMX with erythromycin ([@CD008625-bbs2-0004]; [@CD008625-bbs2-0016]) and found no statistically significant differences ([Analysis 14.1](#CD008625-fig-01401){ref-type="fig"}; [Analysis 14.2](#CD008625-fig-01402){ref-type="fig"}; [Analysis 14.3](#CD008625-fig-01403){ref-type="fig"}).

A single trial compared TMP‐SMX with norfloxacin ([@CD008625-bbs2-0026]), but reported only diarrhoea duration; it found no significant difference between the drugs (data not shown).

### Section 3. Short versus long duration of treatment (mean difference \< 0 and risk ratio \< 1 in favour of short duration) {#CD008625-sec3-0028}

Only the few trials (eight) comparing the same antimicrobial or antimicrobial class were included in this comparison. We divided the trials into subgroups according to the effective duration of treatment in the long treatment arm (24, 48, 72, or 96 hours). The duration of treatment in the short treatment arm was always shorter than 24 hours. This comparison is summarized in [Table 7](#CD008625-tbl-0007){ref-type="table"}.

For clinical outcomes; one trial found that three days of norfloxacin (400 mg twice daily) was superior to a single dose (800 mg), but the remaining trials found no statistically significant benefits with longer durations; diarrhoea duration (seven trials, [Analysis 15.1](#CD008625-fig-01501){ref-type="fig"}), stool volume (eight trials, [Analysis 15.2](#CD008625-fig-01502){ref-type="fig"}), hydration requirements (six trials, [Analysis 15.3](#CD008625-fig-01503){ref-type="fig"}), clinical failure (two trials, [Analysis 15.5](#CD008625-fig-01505){ref-type="fig"}).

In three trials comparing long and short durations of tetracycline, doxycycline and furazolidine respectively, there was a consistent reduction in the duration of pathogen excretion (MD 0.40 days, 95% CI 0.11 to 0.69, three trials, [Analysis 15.4](#CD008625-fig-01504){ref-type="fig"}). There were also more bacteriological failures with shorter treatment (RR 1.53, 95% CI 1.01 to 2.32, [Analysis 15.6](#CD008625-fig-01506){ref-type="fig"}), although the trials were generally at high risk of bias, and underpowered to detect these effects so provide only low quality evidence of this effect.

### Section 4. Low versus high dose of treatment {#CD008625-sec3-0029}

The identified comparisons are detailed in [Table 27](#CD008625-tbl-0027){ref-type="table"}. As antimicrobials and schedules were different, the studies could not be combined. No differences were detected in any trials for any comparisons, except for a comparison between single‐dose doxycycline 200 mg versus 300 mg for adults (and 4 mg/kg versus 6 mg/kg for children). In this case, an advantage was found with the high dose for diarrhoea duration (two trials) and pathogen excretion duration (one trial, data not shown).Table 5Dose comparisonStudyAntimicrobialLow doseHigh doseDurationPopulation[@CD008625-bbs2-0029]furazolidone200 mg400 mg72 hoursAdults[@CD008625-bbs2-0001]doxycycline 200 mg300 mgSingle doseAdults[@CD008625-bbs2-0008]doxycycline Adults: 200 mg; Children: 4 mg/kgAdults: 300 mg; Children: 6 mg/kgSingle doseAdults and children[@CD008625-bbs2-0017]tetracycline10 mg/kg/day in 4 doses31‐62 mg/kg/day in 4 doses7 daysChildren[@CD008625-bbs2-0015]tetracycline1 g2 gSingle doseAdults

Discussion {#CD008625-sec1-0006}
==========

Summary of main results {#CD008625-sec2-0010}
-----------------------

Overall, antimicrobial therapy shortened the mean duration of diarrhoea by about a day and a half compared to placebo or no treatment (*moderate quality evidence*). It also reduced the total stool volume by 50% (*moderate quality evidence*) and reduced the amount of rehydration fluids required by 40% (*moderate quality evidence*). In addition, antimicrobial therapy reduced the mean duration of fecal excretion of vibrios by almost three days (*moderate quality evidence*). In the presence of adequate supportive care, no deaths were reported in all trials.

There was significant heterogeneity in the magnitude of these benefits, however, attributed to the effect of three main variables. These variables are: 1) allocation concealment, with trials at low risk of selection bias having smaller effects; 2) time point for outcome assessment, with trials with longer intervals between assessments demonstrating greater effects; and 3) the type of antimicrobial, with tetracycline appearing to have larger biological effects than other antibiotics.

The analysis of different antimicrobials included many comparisons ([Figure 3](#CD008625-fig-0003){ref-type="fig"}).Tetracycline was the antibiotic most commonly compared to placebo/no treatment, and in indirect comparisons appeared to have larger effects compared to placebo than other antibiotics. However, in head‐to‐head comparisons tetracycline did not demonstrate significant benefits on either diarrhoea duration or stool volume compared to doxycycline (*low quality evidence*), or ciprofloxacin or norfloxacin (*moderate quality evidence*). Azithromycin has not been compared directly to placebo or tetracycline. However, single dose azithromycin shortened the duration of diarrhoea by over a day compared to ciprofloxacin (*moderate quality evidence*) and by half a day compared to erythromycin (*moderate quality evidence*). Quinolones in general were not more effective than other antibiotics.

When evaluating duration of treatment, long duration (\> 24 hours) reduced the duration of pathogen secretion, and reduced rates of bacteriological failure (*low quality evidence*), but for clinical outcomes short and long treatment duration did not differ significantly.

Overall completeness and applicability of evidence {#CD008625-sec2-0011}
--------------------------------------------------

The above benefits of antibiotics should be considered valid when treating people infected with *V. cholera* strains that are susceptible to the antibiotics used, as was the case in these primary studies. The majority of included trials are now over 20 years old, and bacterial susceptibility is dynamic and may increase or decrease over time dependant on factors such as antibiotic consumption and the emergence of new serotypes. Therefore, some of the included antibiotics may not currently be relevant, due to resistance, but may become relevant again in the future if reversal of resistance occurs, as has been described for tetracycline ([@CD008625-bbs2-0076]). In the ongoing outbreak in Mexico for example, the *V. cholera* strain has reduced susceptibility to quinolones and is resistant to TMP‐SMX, but is susceptible to tetracycline and chloramphenicol ([@CD008625-bbs2-0101]).

Currently, the WHO recommends antimicrobial treatment only for patients with severe dehydration ([@CD008625-bbs2-0098]), and most trials (70%) included in our review mandated some measure of severity at baseline. However, the percentage of patients with severe dehydration at baseline (when reported) ranged between 0% and 100%, and our sub‐group analysis at the trial level found similar or larger effects in those trials recruiting patients with a mixed severity of dehydration. This suggests that the benefits of antibiotics extends to patients without severe dehydration.

Stratifying analyses by age revealed no differences in effects between children and adults. However, only a few trials included just children and thus the current evidence applies mostly to adults. The trials included mostly male participants for technical reasons (stool collection). Although the evidence resulting from these trials directly applies to male patients, we cannot think of any biological reason why antimicrobial therapy should have different effects in males and females.

The effect of antimicrobial treatment on resistance development was not assessed in these studies. In any case, randomized controlled trials are probably not the optimal platform to examine resistance development in cholera.

Quality of the evidence {#CD008625-sec2-0012}
-----------------------

Risk of bias relating to allocation concealment affected the magnitude of effect in comparisons between antimicrobials and placebo/no treatment, with the benefits of antimicrobials exaggerated in trials at high risk for bias. We downgraded the quality of evidence for this comparison based on limitations in the designs for these trials. However, a highly significant benefit was observed in the subgroup of trials at low risk for bias regarding allocation concealment for all outcomes, thus our GRADE classifications were conservative. We did not conduct sensitivity analyses for other methodological limitations of the studies, such as blinding, because the objectively‐assessed outcomes included in our review are relatively resistant to bias once the patient is allocated to one of the study arms ([@CD008625-bbs2-0102]).

Potential biases in the review process {#CD008625-sec2-0013}
--------------------------------------

Many trials did not report *V. cholerae* susceptibility to the antibiotics being tested. Where reported, resistance rates were low; in rare cases, where *V. cholerae* isolates were resistant to the tested antibiotic, we excluded this arm. Our assumption is that, at the time of the trial, resistance to the tested antibiotics was low.

The outcomes of stool volume and requirements for rehydration fluids were reported in different units of measurement in the studies included in our review: either total amount in litres or in mL/kg bodyweight. Although the latter is the more appropriate way of presenting these outcomes, only few trials reported weight‐adjusted results. For both outcomes, the distribution of data was skewed. Meta‐analysis of the (log) ratio of means (or imputed means) served us well in overcoming some of the problems of summarizing non‐normally distributed continuous data. It has been shown empirically that ratio of means meta‐analysis produces treatment effects similar to difference‐based methods ([@CD008625-bbs2-0078]). While these results should be viewed with caution, we believe they are more informative than merely describing the outcomes of individual trials.

We performed several indirect comparisons to complement direct randomized comparisons, which were usually based on few trials. Indirect comparisons are non‐randomized and compare antibiotics used in different settings and circumstances, and thus should be viewed with caution.

Agreements and disagreements with other studies or reviews {#CD008625-sec2-0014}
----------------------------------------------------------

It is generally agreed that antimicrobial therapy helps shorten the duration of disease and should thus be used. In their review, [@CD008625-bbs2-0093] estimated that a one to three day course of antimicrobials shortens recovery time from four to five days to two to three days. Ours is the first systematic review to provide absolute figures for this and other outcomes. This quantification can assist health officials in policy decisions and help develop transmission models for cholera epidemics, such as the ones proposed for the epidemic in Haiti ([@CD008625-bbs2-0068]; [@CD008625-bbs2-0095]).

Tetracycline and azithromycin appear to have advantages over other antibiotics and a possible explanation for this could be their mechanism of action. Both of these antimicrobials inhibit protein synthesis and so may directly inhibit the synthesis of the protein enterotoxin responsible for cholera symptoms.

Authors\' conclusions {#CD008625-sec1-0007}
=====================

The current evidence supports the use of antibiotics to reduce the duration and severity of cholera, and to reduce the duration of pathogen excretion. The benefits shown in this review are relevant to the treatment of individual patients, but they may also extend to other patients by curtailing pathogen excretion and so interrupting transmission during epidemics.While patients with severe dehydration are most at risk of death, the benefits of antibiotics probably extend to those with less severe degrees of dehydration. Treatment of these groups during epidemics may also help to ease pressure on health services and decrease transmission.The choice of antibiotic will depend on the drug susceptibility of the epidemic strain, but the evidence supports the use of tetracycline or azithromycin when isolates are susceptible to these antibiotics.Trials assessing the efficacy of antimicrobial treatment among cholera patients with mild or no dehydration are needed. These and other studies (randomized or observational) should attempt to examine the effects of antimicrobial treatment on the spread of cholera and on outbreak containment. Since resistance of *V. cholerae* to antimicrobials is an issue of great importance and rising concern, future trials should monitor and report on resistance development in persisting isolates and on baseline resistance profiles throughout the duration of the trial. In this review, we have shown the effect of bias in randomized controlled trials on results. Future trials should adhere to low‐risk allocation concealment methods for randomization and include women as well as men.A trial comparing azithromycin with tetracycline, both given for the same effective duration (eg single dose azithromycin versus three to four days of tetracycline) would be interesting, since azithromycin has so far only been compared with erythromycin and ciprofloxacin given for shorter durations.  

We thank the Cochrane Infectious Diseases Group Editorial staff for their support. The editorial base for the Cochrane Infectious Diseases Group is funded by UKaid from the UK Government for the benefit of low‐ and middle‐income countries.

Comparison 1Antimicrobial versus placebo/no treatmentOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Diarrhoea duration](#CD008625-fig-00101){ref-type="fig"}Analysis 1.1Comparison 1 Antimicrobial versus placebo/no treatment, Outcome 1 Diarrhoea duration.181479Mean Difference (IV, Random, 95% CI)‐36.77 \[‐43.51, ‐30.03\]1.1 Norfloxacin3123Mean Difference (IV, Random, 95% CI)‐10.80 \[‐14.13, ‐7.48\]1.2 Ciprofloxacin148Mean Difference (IV, Random, 95% CI)‐43.37 \[‐57.48, ‐29.27\]1.3 Tetracycline11665Mean Difference (IV, Random, 95% CI)‐47.38 \[‐52.36, ‐42.41\]1.4 Doxycycline391Mean Difference (IV, Random, 95% CI)‐25.44 \[‐38.90, ‐11.99\]1.5 Erythromycin246Mean Difference (IV, Random, 95% CI)‐33.73 \[‐56.53, ‐10.92\]1.6 TMP‐SMX4100Mean Difference (IV, Random, 95% CI)‐30.76 \[‐49.33, ‐12.18\]1.7 Chloramphenicol3196Mean Difference (IV, Random, 95% CI)‐37.17 \[‐50.14, ‐24.20\]1.8 Furazolidone4210Mean Difference (IV, Random, 95% CI)‐34.12 \[‐49.52, ‐18.72\][2 Stool Volume](#CD008625-fig-00102){ref-type="fig"}Analysis 1.2Comparison 1 Antimicrobial versus placebo/no treatment, Outcome 2 Stool Volume.171536Ratio of means (Random, 95% CI)0.50 \[0.45, 0.56\]2.1 Norfloxacin298Ratio of means (Random, 95% CI)0.61 \[0.51, 0.74\]2.2 Ciprofloxacin148Ratio of means (Random, 95% CI)0.42 \[0.22, 0.82\]2.3 Tetracycline12720Ratio of means (Random, 95% CI)0.44 \[0.39, 0.50\]2.4 Doxycycline391Ratio of means (Random, 95% CI)0.64 \[0.51, 0.81\]2.5 Erythromycin284Ratio of means (Random, 95% CI)0.81 \[0.48, 1.35\]2.6 TMP‐SMX126Ratio of means (Random, 95% CI)0.89 \[0.46, 1.70\]2.7 Chloramphenicol3196Ratio of means (Random, 95% CI)0.54 \[0.32, 0.90\]2.8 Furazolidone4210Ratio of means (Random, 95% CI)0.49 \[0.33, 0.74\]2.9 Ampicillin163Ratio of means (Random, 95% CI)0.57 \[0.42, 0.79\][3 Deaths](#CD008625-fig-00103){ref-type="fig"}Analysis 1.3Comparison 1 Antimicrobial versus placebo/no treatment, Outcome 3 Deaths.6299Risk Difference (M‐H, Fixed, 95% CI)0.0 \[‐0.05, 0.05\]3.1 Norfloxacin298Risk Difference (M‐H, Fixed, 95% CI)0.0 \[‐0.07, 0.07\]3.2 Tetracycline4103Risk Difference (M‐H, Fixed, 95% CI)0.0 \[‐0.08, 0.08\]3.3 Doxycycline265Risk Difference (M‐H, Fixed, 95% CI)0.0 \[‐0.11, 0.11\]3.4 Furazolidone133Risk Difference (M‐H, Fixed, 95% CI)0.0 \[‐0.16, 0.16\][4 Clinical failure](#CD008625-fig-00104){ref-type="fig"}Analysis 1.4Comparison 1 Antimicrobial versus placebo/no treatment, Outcome 4 Clinical failure.101023Risk Ratio (M‐H, Random, 95% CI)0.21 \[0.13, 0.34\]4.1 Fleroxacin1145Risk Ratio (M‐H, Random, 95% CI)0.38 \[0.24, 0.62\]4.2 Tetracycline6431Risk Ratio (M‐H, Random, 95% CI)0.10 \[0.05, 0.22\]4.3 Erythromycin122Risk Ratio (M‐H, Random, 95% CI)0.47 \[0.20, 1.10\]4.4 TMP‐SMX255Risk Ratio (M‐H, Random, 95% CI)0.33 \[0.17, 0.66\]4.5 Chloramphenicol2185Risk Ratio (M‐H, Random, 95% CI)0.14 \[0.05, 0.40\]4.6 Furazolidone2148Risk Ratio (M‐H, Random, 95% CI)0.59 \[0.23, 1.54\]4.7 Sulfometoxine137Risk Ratio (M‐H, Random, 95% CI)0.03 \[0.00, 0.40\][5 Hydration requirements](#CD008625-fig-00105){ref-type="fig"}Analysis 1.5Comparison 1 Antimicrobial versus placebo/no treatment, Outcome 5 Hydration requirements.111201Ratio of means (Random, 95% CI)0.60 \[0.53, 0.68\]5.1 Norfloxacin298Ratio of means (Random, 95% CI)0.72 \[0.60, 0.86\]5.2 Tetracycline8604Ratio of means (Random, 95% CI)0.50 \[0.43, 0.58\]5.3 Doxycycline266Ratio of means (Random, 95% CI)0.76 \[0.57, 1.02\]5.4 Erythromycin284Ratio of means (Random, 95% CI)0.68 \[0.38, 1.21\]5.5 TMP‐SMX126Ratio of means (Random, 95% CI)0.87 \[0.35, 2.17\]5.6 Chloramphenicol2185Ratio of means (Random, 95% CI)0.55 \[0.34, 0.87\]5.7 Furazolidone275Ratio of means (Random, 95% CI)0.85 \[0.60, 1.21\]5.8 Ampicillin163Ratio of means (Random, 95% CI)0.44 \[0.22, 0.88\][6 Pathogen excretion duration](#CD008625-fig-00106){ref-type="fig"}Analysis 1.6Comparison 1 Antimicrobial versus placebo/no treatment, Outcome 6 Pathogen excretion duration.111009Mean Difference (IV, Random, 95% CI)‐2.74 \[‐3.07, ‐2.40\]6.1 Tetracycline10616Mean Difference (IV, Random, 95% CI)‐3.05 \[‐3.43, ‐2.67\]6.2 TMP‐SMX129Mean Difference (IV, Random, 95% CI)‐3.20 \[‐4.93, ‐1.47\]6.3 Chloramphenicol3196Mean Difference (IV, Random, 95% CI)‐2.43 \[‐3.03, ‐1.82\]6.4 Furazolidone3168Mean Difference (IV, Random, 95% CI)‐2.04 \[‐2.71, ‐1.37\][7 Bacteriological failure](#CD008625-fig-00107){ref-type="fig"}Analysis 1.7Comparison 1 Antimicrobial versus placebo/no treatment, Outcome 7 Bacteriological failure.151147Risk Ratio (M‐H, Random, 95% CI)0.25 \[0.16, 0.39\]7.1 Norfloxacin3142Risk Ratio (M‐H, Random, 95% CI)0.02 \[0.00, 0.11\]7.2 Fleroxacin1145Risk Ratio (M‐H, Random, 95% CI)0.11 \[0.04, 0.32\]7.3 Ciprofloxacin148Risk Ratio (M‐H, Random, 95% CI)0.09 \[0.03, 0.26\]7.4 Tetracycline7320Risk Ratio (M‐H, Random, 95% CI)0.28 \[0.13, 0.64\]7.5 Doxycycline264Risk Ratio (M‐H, Random, 95% CI)0.11 \[0.04, 0.30\]7.6 Erythromycin3108Risk Ratio (M‐H, Random, 95% CI)0.17 \[0.09, 0.33\]7.7 TMP‐SMX494Risk Ratio (M‐H, Random, 95% CI)0.37 \[0.13, 1.05\]7.8 Chloramphenicol115Risk Ratio (M‐H, Random, 95% CI)0.73 \[0.38, 1.41\]7.9 Furazolidone2148Risk Ratio (M‐H, Random, 95% CI)0.72 \[0.25, 2.08\]7.10 Ampicillin163Risk Ratio (M‐H, Random, 95% CI)0.75 \[0.57, 0.99\]

Comparison 2Sensitivity analysis: Antimicrobial versus placebo/no treatment by allocation concealmentOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Diarrhoea duration](#CD008625-fig-00201){ref-type="fig"}Analysis 2.1Comparison 2 Sensitivity analysis: Antimicrobial versus placebo/no treatment by allocation concealment, Outcome 1 Diarrhoea duration.181479Mean Difference (IV, Random, 95% CI)‐36.77 \[‐43.51, ‐30.03\]1.1 Low risk4203Mean Difference (IV, Random, 95% CI)‐25.41 \[‐40.82, ‐10.01\]1.2 Unclear9638Mean Difference (IV, Random, 95% CI)‐34.26 \[‐40.32, ‐28.20\]1.3 High risk5638Mean Difference (IV, Random, 95% CI)‐45.01 \[‐51.01, ‐39.01\][2 Stool Volume](#CD008625-fig-00202){ref-type="fig"}Analysis 2.2Comparison 2 Sensitivity analysis: Antimicrobial versus placebo/no treatment by allocation concealment, Outcome 2 Stool Volume.171536Ratio of means (Random, 95% CI)0.50 \[0.45, 0.56\]2.1 Low risk4207Ratio of means (Random, 95% CI)0.68 \[0.47, 0.99\]2.2 Unclear8700Ratio of means (Random, 95% CI)0.51 \[0.46, 0.58\]2.3 High risk6629Ratio of means (Random, 95% CI)0.42 \[0.36, 0.49\][3 Clinical failure](#CD008625-fig-00203){ref-type="fig"}Analysis 2.3Comparison 2 Sensitivity analysis: Antimicrobial versus placebo/no treatment by allocation concealment, Outcome 3 Clinical failure.101023Risk Ratio (M‐H, Random, 95% CI)0.21 \[0.13, 0.34\]3.1 Low risk4323Risk Ratio (M‐H, Random, 95% CI)0.41 \[0.26, 0.63\]3.2 Unclear3196Risk Ratio (M‐H, Random, 95% CI)0.22 \[0.09, 0.55\]3.3 High risk3504Risk Ratio (M‐H, Random, 95% CI)0.08 \[0.04, 0.17\][4 Hydration requirements](#CD008625-fig-00204){ref-type="fig"}Analysis 2.4Comparison 2 Sensitivity analysis: Antimicrobial versus placebo/no treatment by allocation concealment, Outcome 4 Hydration requirements.111201Ratio of means (Random, 95% CI)0.60 \[0.53, 0.68\]4.1 Low risk4203Ratio of means (Random, 95% CI)0.71 \[0.57, 0.89\]4.2 Unclear4463Ratio of means (Random, 95% CI)0.59 \[0.49, 0.71\]4.3 High risk3535Ratio of means (Random, 95% CI)0.50 \[0.43, 0.58\][5 Pathogen excretion duration](#CD008625-fig-00205){ref-type="fig"}Analysis 2.5Comparison 2 Sensitivity analysis: Antimicrobial versus placebo/no treatment by allocation concealment, Outcome 5 Pathogen excretion duration.111009Mean Difference (IV, Random, 95% CI)‐2.74 \[‐3.07, ‐2.40\]5.1 Low risk143Mean Difference (IV, Random, 95% CI)‐3.5 \[‐3.83, ‐3.17\]5.2 Unclear5359Mean Difference (IV, Random, 95% CI)‐2.26 \[‐2.69, ‐1.83\]5.3 High risk5607Mean Difference (IV, Random, 95% CI)‐3.07 \[‐3.43, ‐2.71\][6 Bacteriological failure](#CD008625-fig-00206){ref-type="fig"}Analysis 2.6Comparison 2 Sensitivity analysis: Antimicrobial versus placebo/no treatment by allocation concealment, Outcome 6 Bacteriological failure.151147Risk Ratio (M‐H, Random, 95% CI)0.25 \[0.16, 0.39\]6.1 Low risk4215Risk Ratio (M‐H, Random, 95% CI)0.35 \[0.14, 0.88\]6.2 Unclear10912Risk Ratio (M‐H, Random, 95% CI)0.23 \[0.13, 0.39\]6.3 High risk120Risk Ratio (M‐H, Random, 95% CI)0.05 \[0.00, 0.72\]

Comparison 3Sensitivity analysis: Antimicrobial versus placebo/no treatment by time outcome definitionsOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Diarrhoea duration by outcome definitions](#CD008625-fig-00301){ref-type="fig"}Analysis 3.1Comparison 3 Sensitivity analysis: Antimicrobial versus placebo/no treatment by time outcome definitions, Outcome 1 Diarrhoea duration by outcome definitions.181479Mean Difference (IV, Random, 95% CI)‐36.77 \[‐43.51, ‐30.03\]1.1 Vague time definitions9441Mean Difference (IV, Random, 95% CI)‐28.51 \[‐36.65, ‐20.38\]1.2 8 hours periods91038Mean Difference (IV, Random, 95% CI)‐42.21 \[‐47.64, ‐36.78\][2 Clinical failure at 48/72/96 hours](#CD008625-fig-00302){ref-type="fig"}Analysis 3.2Comparison 3 Sensitivity analysis: Antimicrobial versus placebo/no treatment by time outcome definitions, Outcome 2 Clinical failure at 48/72/96 hours.10Risk Ratio (M‐H, Random, 95% CI)Subtotals only2.1 48 hours2198Risk Ratio (M‐H, Random, 95% CI)0.37 \[0.20, 0.70\]2.2 72 hours6307Risk Ratio (M‐H, Random, 95% CI)0.37 \[0.27, 0.51\]2.3 96 hours4608Risk Ratio (M‐H, Random, 95% CI)0.13 \[0.04, 0.37\][3 Bacteriological failure 48/72/96 sub totals only](#CD008625-fig-00303){ref-type="fig"}Analysis 3.3Comparison 3 Sensitivity analysis: Antimicrobial versus placebo/no treatment by time outcome definitions, Outcome 3 Bacteriological failure 48/72/96 sub totals only.15Risk Ratio (M‐H, Random, 95% CI)Subtotals only3.1 48 hours10747Risk Ratio (M‐H, Random, 95% CI)0.32 \[0.19, 0.54\]3.2 72 hours7474Risk Ratio (M‐H, Random, 95% CI)0.20 \[0.11, 0.37\]3.3 96 hours4313Risk Ratio (M‐H, Random, 95% CI)0.32 \[0.14, 0.74\]

Comparison 4Antimicrobial versus placebo/no treatment subgrouped by severity of dehydrationOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Diarrhoea duration](#CD008625-fig-00401){ref-type="fig"}Analysis 4.1Comparison 4 Antimicrobial versus placebo/no treatment subgrouped by severity of dehydration, Outcome 1 Diarrhoea duration.181479Mean Difference (IV, Random, 95% CI)‐36.77 \[‐43.51, ‐30.03\]1.1 100% severe dehydration6296Mean Difference (IV, Random, 95% CI)‐26.24 \[‐35.66, ‐16.82\]1.2 Others121183Mean Difference (IV, Random, 95% CI)‐41.31 \[‐45.99, ‐36.62\][2 Stool Volume](#CD008625-fig-00402){ref-type="fig"}Analysis 4.2Comparison 4 Antimicrobial versus placebo/no treatment subgrouped by severity of dehydration, Outcome 2 Stool Volume.171575Ratio of means (Random, 95% CI)0.50 \[0.45, 0.56\]2.1 100% severe dehydration6263Ratio of means (Random, 95% CI)0.58 \[0.50, 0.66\]2.2 Others111312Ratio of means (Random, 95% CI)0.48 \[0.42, 0.56\][3 Clinical failure](#CD008625-fig-00403){ref-type="fig"}Analysis 4.3Comparison 4 Antimicrobial versus placebo/no treatment subgrouped by severity of dehydration, Outcome 3 Clinical failure.101023Risk Ratio (M‐H, Random, 95% CI)0.21 \[0.13, 0.34\]3.1 100% severe dehydration273Risk Ratio (M‐H, Random, 95% CI)0.17 \[0.04, 0.68\]3.2 Others8950Risk Ratio (M‐H, Random, 95% CI)0.22 \[0.13, 0.37\][4 Hydration requirements](#CD008625-fig-00404){ref-type="fig"}Analysis 4.4Comparison 4 Antimicrobial versus placebo/no treatment subgrouped by severity of dehydration, Outcome 4 Hydration requirements.111201Ratio of means (Random, 95% CI)0.60 \[0.53, 0.68\]4.1 100% severe dehydration3186Ratio of means (Random, 95% CI)0.73 \[0.65, 0.83\]4.2 Others81015Ratio of means (Random, 95% CI)0.55 \[0.47, 0.64\]

Comparison 5Antimicrobial vs. placebo/no treatment subgrouped by antimicrobial resistanceOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Bacteriological failure arms with no resistance only](#CD008625-fig-00501){ref-type="fig"}Analysis 5.1Comparison 5 Antimicrobial vs. placebo/no treatment subgrouped by antimicrobial resistance, Outcome 1 Bacteriological failure arms with no resistance only.9611Risk Ratio (M‐H, Random, 95% CI)0.13 \[0.06, 0.27\]1.1 Norfloxacin3142Risk Ratio (M‐H, Random, 95% CI)0.02 \[0.00, 0.11\]1.2 Fleroxacin1145Risk Ratio (M‐H, Random, 95% CI)0.11 \[0.04, 0.32\]1.3 Ciprofloxacin148Risk Ratio (M‐H, Random, 95% CI)0.09 \[0.03, 0.26\]1.4 Tetracycline3185Risk Ratio (M‐H, Random, 95% CI)0.24 \[0.09, 0.62\]1.5 Doxycycline138Risk Ratio (M‐H, Random, 95% CI)0.10 \[0.03, 0.41\]1.6 Erythromycin124Risk Ratio (M‐H, Random, 95% CI)0.03 \[0.00, 0.44\]1.7 TMP‐SMX129Risk Ratio (M‐H, Random, 95% CI)0.8 \[0.27, 2.38\]

Comparison 6Azithromycin versus ciprofloxacinOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Diarrhoea duration](#CD008625-fig-00601){ref-type="fig"}Analysis 6.1Comparison 6 Azithromycin versus ciprofloxacin, Outcome 1 Diarrhoea duration.2375Mean Difference (IV, Random, 95% CI)‐32.43 \[‐62.90, ‐1.95\][2 Stool Volume](#CD008625-fig-00602){ref-type="fig"}Analysis 6.2Comparison 6 Azithromycin versus ciprofloxacin, Outcome 2 Stool Volume.1195Ratio of means (Random, 95% CI)0.35 \[0.28, 0.44\][3 Hydration requirements](#CD008625-fig-00603){ref-type="fig"}Analysis 6.3Comparison 6 Azithromycin versus ciprofloxacin, Outcome 3 Hydration requirements.2362Ratio of means (Random, 95% CI)0.66 \[0.52, 0.83\][4 Clinical failure](#CD008625-fig-00604){ref-type="fig"}Analysis 6.4Comparison 6 Azithromycin versus ciprofloxacin, Outcome 4 Clinical failure.2375Risk Ratio (M‐H, Fixed, 95% CI)0.32 \[0.23, 0.44\][5 Bacteriological failure](#CD008625-fig-00605){ref-type="fig"}Analysis 6.5Comparison 6 Azithromycin versus ciprofloxacin, Outcome 5 Bacteriological failure.2375Risk Ratio (M‐H, Fixed, 95% CI)0.23 \[0.16, 0.34\]

Comparison 7Azithromycin versus erythromycinOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Diarrhoea duration](#CD008625-fig-00701){ref-type="fig"}Analysis 7.1Comparison 7 Azithromycin versus erythromycin, Outcome 1 Diarrhoea duration.2179Mean Difference (IV, Random, 95% CI)‐12.05 \[‐22.02, ‐2.08\][2 Stool Volume](#CD008625-fig-00702){ref-type="fig"}Analysis 7.2Comparison 7 Azithromycin versus erythromycin, Outcome 2 Stool Volume.2172Ratio of means (Random, 95% CI)0.69 \[0.56, 0.85\][3 Hydration requirements](#CD008625-fig-00703){ref-type="fig"}Analysis 7.3Comparison 7 Azithromycin versus erythromycin, Outcome 3 Hydration requirements.2179Ratio of means (Random, 95% CI)0.77 \[0.56, 1.05\][4 Clinical failure](#CD008625-fig-00704){ref-type="fig"}Analysis 7.4Comparison 7 Azithromycin versus erythromycin, Outcome 4 Clinical failure.1Risk Ratio (M‐H, Fixed, 95% CI)Subtotals only[5 Bacteriological failure](#CD008625-fig-00705){ref-type="fig"}Analysis 7.5Comparison 7 Azithromycin versus erythromycin, Outcome 5 Bacteriological failure.2179Risk Ratio (M‐H, Fixed, 95% CI)1.56 \[0.80, 3.02\]

Comparison 8Tetracycline versus doxycyclineOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Diarrhoea duration](#CD008625-fig-00801){ref-type="fig"}Analysis 8.1Comparison 8 Tetracycline versus doxycycline, Outcome 1 Diarrhoea duration.3230Mean Difference (IV, Random, 95% CI)‐2.01 \[‐8.21, 4.19\][2 Stool Volume](#CD008625-fig-00802){ref-type="fig"}Analysis 8.2Comparison 8 Tetracycline versus doxycycline, Outcome 2 Stool Volume.3230Ratio of means (Random, 95% CI)0.97 \[0.83, 1.14\][3 Deaths](#CD008625-fig-00803){ref-type="fig"}Analysis 8.3Comparison 8 Tetracycline versus doxycycline, Outcome 3 Deaths.266Risk Difference (M‐H, Fixed, 95% CI)0.0 \[‐0.08, 0.08\][4 Hydration requirements](#CD008625-fig-00804){ref-type="fig"}Analysis 8.4Comparison 8 Tetracycline versus doxycycline, Outcome 4 Hydration requirements.3230Ratio of means (Random, 95% CI)0.91 \[0.78, 1.06\][5 Pathogen excretion duration](#CD008625-fig-00805){ref-type="fig"}Analysis 8.5Comparison 8 Tetracycline versus doxycycline, Outcome 5 Pathogen excretion duration.266Mean Difference (IV, Random, 95% CI)‐0.46 \[‐1.03, 0.11\][6 Bacteriological failure](#CD008625-fig-00806){ref-type="fig"}Analysis 8.6Comparison 8 Tetracycline versus doxycycline, Outcome 6 Bacteriological failure.2198Risk Ratio (M‐H, Fixed, 95% CI)0.20 \[0.06, 0.68\]

Comparison 9Tetracycline versus quinoloneOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Diarrhoea duration](#CD008625-fig-00901){ref-type="fig"}Analysis 9.1Comparison 9 Tetracycline versus quinolone, Outcome 1 Diarrhoea duration.3259Mean Difference (IV, Random, 95% CI)‐0.91 \[‐4.53, 2.72\][2 Stool Volume](#CD008625-fig-00902){ref-type="fig"}Analysis 9.2Comparison 9 Tetracycline versus quinolone, Outcome 2 Stool Volume.2234Ratio of means (Random, 95% CI)0.87 \[0.75, 1.02\][3 Deaths](#CD008625-fig-00903){ref-type="fig"}Analysis 9.3Comparison 9 Tetracycline versus quinolone, Outcome 3 Deaths.125Risk Difference (M‐H, Fixed, 95% CI)0.0 \[‐0.14, 0.14\][4 Clinical failure](#CD008625-fig-00904){ref-type="fig"}Analysis 9.4Comparison 9 Tetracycline versus quinolone, Outcome 4 Clinical failure.1202Risk Ratio (M‐H, Fixed, 95% CI)0.67 \[0.33, 1.38\][5 Hydration requirements](#CD008625-fig-00905){ref-type="fig"}Analysis 9.5Comparison 9 Tetracycline versus quinolone, Outcome 5 Hydration requirements.2234Ratio of means (Random, 95% CI)0.98 \[0.90, 1.07\][6 Pathogen excretion duration](#CD008625-fig-00906){ref-type="fig"}Analysis 9.6Comparison 9 Tetracycline versus quinolone, Outcome 6 Pathogen excretion duration.125Mean Difference (IV, Random, 95% CI)0.05 \[‐0.42, 0.52\][7 Bacteriological failure](#CD008625-fig-00907){ref-type="fig"}Analysis 9.7Comparison 9 Tetracycline versus quinolone, Outcome 7 Bacteriological failure.2234Risk Ratio (M‐H, Fixed, 95% CI)0.99 \[0.14, 6.82\]

Comparison 10Tetracycline versus TMP‐SMXOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Diarrhoea duration](#CD008625-fig-01001){ref-type="fig"}Analysis 10.1Comparison 10 Tetracycline versus TMP‐SMX, Outcome 1 Diarrhoea duration.2152Mean Difference (IV, Random, 95% CI)‐6.44 \[‐10.93, ‐1.96\][2 Clinical failure](#CD008625-fig-01002){ref-type="fig"}Analysis 10.2Comparison 10 Tetracycline versus TMP‐SMX, Outcome 2 Clinical failure.2152Risk Ratio (M‐H, Fixed, 95% CI)0.56 \[0.34, 0.92\][3 Pathogen excretion duration](#CD008625-fig-01003){ref-type="fig"}Analysis 10.3Comparison 10 Tetracycline versus TMP‐SMX, Outcome 3 Pathogen excretion duration.145Mean Difference (IV, Random, 95% CI)‐1.10 \[‐1.74, ‐0.46\][4 Bacteriological failure](#CD008625-fig-01004){ref-type="fig"}Analysis 10.4Comparison 10 Tetracycline versus TMP‐SMX, Outcome 4 Bacteriological failure.3173Risk Ratio (M‐H, Fixed, 95% CI)1.19 \[0.71, 2.02\]

Comparison 11Tetracycline versus chloramphenicolOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Diarrhoea duration](#CD008625-fig-01101){ref-type="fig"}Analysis 11.1Comparison 11 Tetracycline versus chloramphenicol, Outcome 1 Diarrhoea duration.3356Mean Difference (IV, Random, 95% CI)‐11.49 \[‐25.93, 2.96\][2 Stool Volume](#CD008625-fig-01102){ref-type="fig"}Analysis 11.2Comparison 11 Tetracycline versus chloramphenicol, Outcome 2 Stool Volume.3356Ratio of means (Random, 95% CI)0.72 \[0.50, 1.04\][3 Clinical failure](#CD008625-fig-01103){ref-type="fig"}Analysis 11.3Comparison 11 Tetracycline versus chloramphenicol, Outcome 3 Clinical failure.2340Risk Ratio (M‐H, Fixed, 95% CI)0.37 \[0.13, 1.04\][4 Hydration requirements](#CD008625-fig-01104){ref-type="fig"}Analysis 11.4Comparison 11 Tetracycline versus chloramphenicol, Outcome 4 Hydration requirements.2340Ratio of means (Random, 95% CI)0.81 \[0.53, 1.24\][5 Pathogen excretion duration](#CD008625-fig-01105){ref-type="fig"}Analysis 11.5Comparison 11 Tetracycline versus chloramphenicol, Outcome 5 Pathogen excretion duration.3356Mean Difference (IV, Random, 95% CI)‐0.96 \[‐1.48, ‐0.44\]

Comparison 12Tetracycline versus furazolidoneOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Diarrhoea duration](#CD008625-fig-01201){ref-type="fig"}Analysis 12.1Comparison 12 Tetracycline versus furazolidone, Outcome 1 Diarrhoea duration.3121Mean Difference (IV, Random, 95% CI)‐14.00 \[‐31.26, ‐0.74\][2 Stool Volume](#CD008625-fig-01202){ref-type="fig"}Analysis 12.2Comparison 12 Tetracycline versus furazolidone, Outcome 2 Stool Volume.3120Ratio of means (Random, 95% CI)0.63 \[0.48, 0.83\][3 Deaths](#CD008625-fig-01203){ref-type="fig"}Analysis 12.3Comparison 12 Tetracycline versus furazolidone, Outcome 3 Deaths.273Risk Difference (M‐H, Fixed, 95% CI)0.0 \[‐0.07, 0.07\][4 Clinical failure](#CD008625-fig-01204){ref-type="fig"}Analysis 12.4Comparison 12 Tetracycline versus furazolidone, Outcome 4 Clinical failure.157Risk Ratio (M‐H, Fixed, 95% CI)0.25 \[0.08, 0.79\][5 Hydration requirements](#CD008625-fig-01205){ref-type="fig"}Analysis 12.5Comparison 12 Tetracycline versus furazolidone, Outcome 5 Hydration requirements.282Ratio of means (Random, 95% CI)0.63 \[0.46, 0.87\][6 Pathogen excretion duration](#CD008625-fig-01206){ref-type="fig"}Analysis 12.6Comparison 12 Tetracycline versus furazolidone, Outcome 6 Pathogen excretion duration.264Mean Difference (IV, Random, 95% CI)‐0.89 \[‐1.98, 0.20\][7 Bacteriological failure](#CD008625-fig-01207){ref-type="fig"}Analysis 12.7Comparison 12 Tetracycline versus furazolidone, Outcome 7 Bacteriological failure.2105Risk Ratio (M‐H, Fixed, 95% CI)0.69 \[0.45, 1.08\]

Comparison 13Doxycycline versus quinolonesOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Diarrhoea duration](#CD008625-fig-01301){ref-type="fig"}Analysis 13.1Comparison 13 Doxycycline versus quinolones, Outcome 1 Diarrhoea duration.3126Mean Difference (IV, Random, 95% CI)4.64 \[‐2.14, 11.42\][2 Stool Volume](#CD008625-fig-01302){ref-type="fig"}Analysis 13.2Comparison 13 Doxycycline versus quinolones, Outcome 2 Stool Volume.4435Ratio of means (Random, 95% CI)1.01 \[0.82, 1.25\][3 Deaths](#CD008625-fig-01303){ref-type="fig"}Analysis 13.3Comparison 13 Doxycycline versus quinolones, Outcome 3 Deaths.154Risk Difference (M‐H, Fixed, 95% CI)0.0 \[‐0.07, 0.07\][4 Hydration requirements](#CD008625-fig-01304){ref-type="fig"}Analysis 13.4Comparison 13 Doxycycline versus quinolones, Outcome 4 Hydration requirements.287Ratio of means (Random, 95% CI)1.18 \[1.02, 1.35\][5 Bacteriological failure](#CD008625-fig-01305){ref-type="fig"}Analysis 13.5Comparison 13 Doxycycline versus quinolones, Outcome 5 Bacteriological failure.4386Risk Ratio (M‐H, Fixed, 95% CI)5.84 \[2.70, 12.65\]

Comparison 14TMP‐SMX versus erythromycinOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Diarrhoea duration](#CD008625-fig-01401){ref-type="fig"}Analysis 14.1Comparison 14 TMP‐SMX versus erythromycin, Outcome 1 Diarrhoea duration.268Mean Difference (IV, Random, 95% CI)5.39 \[‐7.82, 18.60\][2 Clinical failure](#CD008625-fig-01402){ref-type="fig"}Analysis 14.2Comparison 14 TMP‐SMX versus erythromycin, Outcome 2 Clinical failure.133Risk Ratio (M‐H, Fixed, 95% CI)0.5 \[0.14, 1.76\][3 Bacteriological failure](#CD008625-fig-01403){ref-type="fig"}Analysis 14.3Comparison 14 TMP‐SMX versus erythromycin, Outcome 3 Bacteriological failure.268Risk Difference (M‐H, Fixed, 95% CI)‐0.02 \[‐0.16, 0.12\]

Comparison 15Short versus long duration of treatmentOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Diarrhoea duration](#CD008625-fig-01501){ref-type="fig"}Analysis 15.1Comparison 15 Short versus long duration of treatment, Outcome 1 Diarrhoea duration.7431Mean Difference (IV, Random, 95% CI)0.34 \[‐4.65, 5.32\]1.1 Long duration 24 hours288Mean Difference (IV, Random, 95% CI)‐5.30 \[‐24.64, 14.04\]1.2 Long duration 48 hours2204Mean Difference (IV, Random, 95% CI)1.01 \[‐2.26, 4.27\]1.3 Long duration 72 hours285Mean Difference (IV, Random, 95% CI)3.63 \[‐16.16, 23.43\]1.4 Long duration 96 hours154Mean Difference (IV, Random, 95% CI)6.60 \[0.84, 12.36\][2 Stool Volume](#CD008625-fig-01502){ref-type="fig"}Analysis 15.2Comparison 15 Short versus long duration of treatment, Outcome 2 Stool Volume.8486Ratio of means (Random, 95% CI)1.05 \[0.94, 1.18\]2.1 Long duration 24 hours288Ratio of means (Random, 95% CI)0.98 \[0.72, 1.33\]2.2 Long duration 48 hours2204Ratio of means (Random, 95% CI)0.99 \[0.83, 1.17\]2.3 Long duration 72 hours285Ratio of means (Random, 95% CI)1.03 \[0.76, 1.39\]2.4 Long duration 96 hours2109Ratio of means (Random, 95% CI)1.15 \[0.82, 1.61\][3 Hydration requirements](#CD008625-fig-01503){ref-type="fig"}Analysis 15.3Comparison 15 Short versus long duration of treatment, Outcome 3 Hydration requirements.6403Ratio of means (Random, 95% CI)1.10 \[0.99, 1.22\]3.1 Long duration 24 hours148Ratio of means (Random, 95% CI)1.01 \[0.66, 1.55\]3.2 Long duration 48 hours2204Ratio of means (Random, 95% CI)1.08 \[0.91, 1.28\]3.3 Long duration 72 hours132Ratio of means (Random, 95% CI)0.86 \[0.27, 2.76\]3.4 Long duration 96 hours2119Ratio of means (Random, 95% CI)1.07 \[0.83, 1.38\][4 Pathogen excretion duration](#CD008625-fig-01504){ref-type="fig"}Analysis 15.4Comparison 15 Short versus long duration of treatment, Outcome 4 Pathogen excretion duration.3141Mean Difference (IV, Random, 95% CI)0.40 \[0.11, 0.69\]4.1 Long duration 24 hours148Mean Difference (IV, Random, 95% CI)0.90 \[‐0.21, 2.01\]4.2 Long duration 48 hours140Mean Difference (IV, Random, 95% CI)0.25 \[0.03, 0.47\]4.3 Long duration 72 hours153Mean Difference (IV, Random, 95% CI)0.59 \[0.16, 1.01\][5 Clinical failure](#CD008625-fig-01505){ref-type="fig"}Analysis 15.5Comparison 15 Short versus long duration of treatment, Outcome 5 Clinical failure.2Odds Ratio (M‐H, Fixed, 95% CI)Totals not selected5.1 Long duration 72 hours1Odds Ratio (M‐H, Fixed, 95% CI)0.0 \[0.0, 0.0\]5.2 Long duration 96 hours1Odds Ratio (M‐H, Fixed, 95% CI)0.0 \[0.0, 0.0\][6 Bacteriological failure](#CD008625-fig-01506){ref-type="fig"}Analysis 15.6Comparison 15 Short versus long duration of treatment, Outcome 6 Bacteriological failure.9672Risk Ratio (M‐H, Fixed, 95% CI)1.53 \[1.01, 2.32\]6.1 Long duration 24 hours148Risk Ratio (M‐H, Fixed, 95% CI)7.58 \[0.41, 139.32\]6.2 Long duration 48 hours2286Risk Ratio (M‐H, Fixed, 95% CI)1.73 \[0.87, 3.45\]6.3 Long duration 72 hours3125Risk Ratio (M‐H, Fixed, 95% CI)1.12 \[0.58, 2.17\]6.4 Long duration 96 hours3213Risk Ratio (M‐H, Fixed, 95% CI)1.54 \[0.61, 3.90\]

Methods of pooling outcomes dependent on weight were changed from standardized mean differences (SMDs) to ratio of means. SMDs had no clinical meaning and could not be translated into a clinically meaningful outcome because of the varying standard deviations reported in the trials. The SMD analysis also abolished the heterogeneity that was apparent when looking at the results of the individual trials.We decided to exclude antimicrobials that are not currently in clinical use for treating cholera.With regards to data analysis, in order to include all patients in trials with multiple study arms, we acted as suggested in the *Cochrane Handbook for Systematic Reviews of Interventions* ([@CD008625-bbs2-0083]). For dichotomous results, we divided the number of events and participants in the placebo arm, and for continuous results we divided the number of participants and used mean and standard deviation as is. This was done instead of using the antimicrobial \'hierarchy\' first designed in the protocol for this review, which allowed the inclusion of only one study arm versus, placebo from these trials.We added subgroup analyses based on timing definitions for monitoring and severity of dehydration at baseline. We omitted sensitivity analyses regarding intention to treat in the outcome of clinical failure.We changed the time definitions for the outcomes of clinical failure and bacteriological failure.We did not include the outcomes of clinical and bacteriological relapse in our review. The reason for this decision was that relapse could occur only in patients that had been cured (for example, patients who never stopped purging could never relapse). This definition caused a bias against the arms receiving antimicrobial treatment, which seemed to experience relapse more than the placebo/no treatment arms.

Characteristics of included studies \[ordered by study ID\] {#CD008625-sec2-0017}
===========================================================

[@CD008625-bbs2-0001]MethodsRandomized controlled trial.\
Follow up duration: until faecal cultures were negative for two consecutive days.ParticipantsLocation: Dhaka, Bangaladesh.\
Years: 1986 to 1987.\
Participants: age \> 15 yrs; 40% females.\
Number of participants: 261 randomized, 246 evaluated.\
Cholera serogroup: O1 (biotype: El‐tor, classical).\
Exclusion due to previous use of antibiotics: yes.\
Exclusion due to severity of symptoms: no.InterventionsPO Tetracycline: 500 mg four times per day for 2 days.\
PO Doxycycline: 300 mg single dose.\
PO Doxycycline: 200 mg single dose.\
Resistance to intervention: no resistance.OutcomesDiarrhoea duration in hours (defined as: duration of diarrhoea from entry to study until 8 hours have passed since last watery stool).\
Stool volume in mL/kg body weight (defined as: volume of diarrhoea from entry to study until last watery stool).\
Bacteriological failure (defined as: number of patients with *V. cholerae* in stool on day 3 of study).NotesEthics committee involved: yes.\
consent requested and given from study participants: yes.\
Type of hydration used in study: IV hydration, glucose ORS.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskNumber code kept in WHO headquarters in Geneva (thus assumed code is random).Allocation concealment (selection bias)Low riskSealed numbered envelopes.Blinding (performance bias and detection bias) All outcomesLow riskDouble blind, identical looking pills.Incomplete outcome data (attrition bias) Diarrhoea durationLow riskOnly 15 out of 261 patients were not evaluated, reasons were not specified.Incomplete outcome data (attrition bias) Stool volumeLow riskOnly 15 out of 261 patients were not evaluated, reasons were not specified.Selective reporting (reporting bias)High riskStudy outcomes were not specified at all in the methods section.Other biasUnclear riskStudy sponsor: academic. Drugs provided by Pfizer.[@CD008625-bbs2-0002]MethodsRandomized controlled trial.\
Follow up duration: not specified, probably while in hospital.ParticipantsLocation: Kolkata, India.\
Years: not specified.\
Participants: age \> 18 yrs. No females participated.\
Number of participants: 78 randomized, 37 evaluated.\
Cholera serogroup: O1.\
Exclusion due to previous use of antibiotics: yes.\
Exclusion due to severity of symptoms: no.InterventionsPO Norfloxacin: 400 mg twice per day for 5 days.\
PO TMP‐SMX: (Trimetoprim: 160 mg; Sulfamethoxazol: 800 mg) twice per day for 5 days.\
PO Placebo: 1 Tab. twice per day for 5 days.\
Resistance to intervention: 100% resistance to TMP‐SMX, 0% resistance to Norfloxacin.OutcomesDiarrhoea duration in hours (definition not specified).\
Total stool volume in litres (definition not specified in study).\
Deaths (definition not specified in study, probably while in hospital).\
Bacteriological failure (defined as: number of patients with *V. cholerae* in stool on day 3 of study).NotesEthics committee involved: not specified.\
consent requested and given from study participants: yes.\
Type of hydration used in study: IV hydration, ORS according to WHO recommendations.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandom number table.Allocation concealment (selection bias)Low riskIdentical pills coded according to a code that was opened after completion of the study.Blinding (performance bias and detection bias) All outcomesLow riskDouble blind.Incomplete outcome data (attrition bias) Diarrhoea durationHigh riskApproximately 50% of the patients in each group were not evaluated, reasons were not specified.Incomplete outcome data (attrition bias) Stool volumeHigh riskApproximately 50% of the patients in each group were not evaluated, reasons were not specified.Selective reporting (reporting bias)Unclear riskPrimary outcomes were not specified.Other biasHigh riskStudy sponsor: academic, Ranbaxy Laboratories Ltd.[@CD008625-bbs2-0003]MethodsRandomized controlled trial.\
Follow up duration: not specified, probably while in hospital.ParticipantsLocation: Kolkata, India.\
Years: 2000 to 2002.\
Participants: children. No females participated.\
Number of participants: 80 randomized, 56 evaluated.\
Cholera serogroup: O1, O139.\
Exclusion due to previous use of antibiotics: yes.\
Exclusion due to severity of symptoms: no.InterventionsPO Azithromycin: 10 mg/kg once per day for 3 days; PO placebo matching Erythromycin.\
PO Erythromycin: 12.5 mg/kg four times per day for 3 days; PO placebo matching Azithromycin.\
Resistance to intervention: no resistance.OutcomesDiarrhoea duration in hours (definition not specified).\
Total stool volume in litres (definition not specified in study).\
Deaths (full recovery stated for all study participants).\
Bacteriological failure (all patients stopped secreting vibrios in stool within first day of treatment).NotesEthics committee involved: yes.\
consent requested and given from study participants: yes.\
Type of hydration used in study: IV hydration, ORS according to WHO recommendations.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandom number table (using block randomizations of various block lengths).Allocation concealment (selection bias)Low riskSealed numbered envelopes.Blinding (performance bias and detection bias) All outcomesLow riskDouble blind.Incomplete outcome data (attrition bias) Diarrhoea durationHigh risk11 out of 40 in the azithromycin group and 13 out of 40 in the erythromycin group were not evaluated, reasons were not specified.Incomplete outcome data (attrition bias) Stool volumeHigh risk11 out of 40 in the azithromycin group and 13 out of 40 in the erythromycin group were not evaluated, reasons were not specified.Selective reporting (reporting bias)Low riskStudy outcomes were clearly specified and reported.Other biasUnclear riskSponsor not stated.[@CD008625-bbs2-0004]MethodsRandomized controlled trial.\
Follow up duration: not specified, while in hospital.ParticipantsLocation: Mogadishu, Somalia.\
Years: not specified.\
Participants: children and adults. Female participation not specified.\
Number of participants: 47 randomized, 47 evaluated.\
Cholera serogroup: O1.\
Exclusion due to previous use of antibiotics: yes.\
Exclusion due to severity of symptoms: no.InterventionsPO Erythromycin: adults 800 mg; children 20 mg/kg twice per day until discharge.\
PO TMP‐SMX: (adults: Trimetoprim 160 mg, Sulfametoxazol 800 mg; children: Trimetoprim 4 mg/kg; Sulfametoxazol 20 mg/kg) twice per day until discharge.\
PO Dextrose (as placebo): twice per day until discharge.\
Resistance to intervention: 2% resistance to TMP‐SMX, 0% resistance to Erythromycin.OutcomesDiarrhoea duration in days (definition not specified).\
Bacteriological failure (no. of patients with stool free of vibrios after 24, 48, and 72 hours).NotesEthics committee involved: not specified.\
consent requested and given from study participants: not specified.\
Type of hydration used in study: IV hydration.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNo description.Allocation concealment (selection bias)Unclear riskNo description.Blinding (performance bias and detection bias) All outcomesHigh riskPlacebo was used, but it was cherry flavoured.Incomplete outcome data (attrition bias) Diarrhoea durationLow riskAll patients randomized to each group were evaluated.Incomplete outcome data (attrition bias) Stool volumeUnclear riskOutcome not reported.Selective reporting (reporting bias)Unclear riskTime point for outcome assessment not defined.Other biasLow riskStudy sponsor: academic.[@CD008625-bbs2-0005]MethodsRandomized controlled trial.\
Follow up duration: 5 days.ParticipantsLocation: multicenter (Thailand, Indonesia, Ivory coast, Mexico, Israel, Italy).\
Years: 1987 to 1989.\
Participants: adults. Female participation not specified.\
Number of participants: 508 randomized, 46 evaluated.\
Cholera serogroup: not specified.\
Exclusion due to previous use of antibiotics: yes.\
Exclusion due to severity of symptoms: yes.InterventionsPO Fleroxacin: 400 mg once per day for 3 days.\
PO Fleroxacin: 400 mg single dose; PO placebo once per day for the next two days.\
PO Placebo: once per day for 3 days.\
Resistance to intervention: no resistance.OutcomesClinical failure (defined as: continuation of diarrhoea over 48 hours since beginning of treatment).\
Bacteriological failure (defined as: stool culture positive for *V. cholerae* on day 3 of study).NotesEthics committee involved: not specified.\
consent requested and given from study participants: yes.\
Type of hydration used in study: IV hydration.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandom numbers generated by a computer.Allocation concealment (selection bias)Low riskNumber code was not revealed to investigators until the study ended.Blinding (performance bias and detection bias) All outcomesLow riskDoubel blind. All patients received identical looking pills, in the same amount.Incomplete outcome data (attrition bias) Diarrhoea durationUnclear riskOutcome not reported.Incomplete outcome data (attrition bias) Stool volumeUnclear riskOutcome not reported.Selective reporting (reporting bias)Unclear riskTime point for outcome assessment not defined.Other biasUnclear riskStudy sponsor: manufacturer of Fleroxacin.[@CD008625-bbs2-0006]MethodsQuasi‐randomized controlled trial.\
Follow up duration: at least 7 days.ParticipantsLocation: Kolkata, India.\
Years: 1963.\
Participants: adults. No females participated.\
Number of participants: 20 randomized, 20 evaluated.\
Cholera serogroup: O1.\
Exclusion due to previous use of antibiotics: not specified.\
Exclusion due to severity of symptoms: no.InterventionsIV Tetracycline: 100 mg four times per day for the first day. PO Tetracycline: 500 mg four times per day for 3 days.\
No treatment.\
Resistance to intervention: not specified.OutcomesTotal stool volume in litres (definition not specified in study).\
Deaths (defined as number of deaths during follow up, information obtained from correspondence with the author).\
Pathogen secretion duration in days (defined as number of days with a positive culture for *V. cholerae*).\
Clinical failure (defined as number of patients with stool volume \> 3450 mL/day after 72 hours of treatment).\
Bacteriological failure (defined as: stool culture positive for *V. cholerae* after 48 and 72 hours of treatment).NotesEthics committee involved: not specified.\
consent requested and given from study participants: not specified.\
Type of hydration used in study: IV hydration, water, barley water.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High riskThe first patient to arrive received no antibiotics and the second received Tetracycline.Allocation concealment (selection bias)High riskPatients received treatment according to time of arrival at the hospital.Blinding (performance bias and detection bias) All outcomesHigh riskControl arm received no treatment.Incomplete outcome data (attrition bias) Diarrhoea durationUnclear riskOutcome not reported.Incomplete outcome data (attrition bias) Stool volumeLow riskAll randomized patients were evaluated.Selective reporting (reporting bias)Unclear riskTime point for outcome assessment not defined.Other biasLow riskStudy sponsor: academic.[@CD008625-bbs2-0007]MethodsRandomized controlled trial.\
Follow up duration: while in hospital, average of 7 days.ParticipantsLocation: Kolkata, India.\
Years: not specified.\
Participants: adults. No females participated.\
Number of participants: 72 randomized, 72 evaluated. Stool positive for *V. cholerae* required for inclusion.\
Cholera serogroup: O1.\
Exclusion due to previous use of antibiotics: not specified.\
Exclusion due to severity of symptoms: no.InterventionsPO Forazolidone: 100 mg four times per day for 3 days.\
PO Forazolidone: 400 mg once per day for 3 days.\
PO Tetracycline: 250 mg four times per day for 3 days.\
Resistance to intervention: not specified.OutcomesDeaths (full recovery stated for all study participants).\
Bacteriological failure (defined as: vibrios in stool after 48 hours from beginning of treatment).\
Bacteriological relapse (defined as: positive rectal swab after a negative one).NotesEthics committee involved: not specified.\
consent requested and given from study participants: not specified.\
Type of hydration used in study: IV hydration.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNo description.Allocation concealment (selection bias)Unclear riskNo description.Blinding (performance bias and detection bias) All outcomesHigh riskPatients received different pills in different amounts.Incomplete outcome data (attrition bias) Diarrhoea durationUnclear riskOutcome not reported.Incomplete outcome data (attrition bias) Stool volumeUnclear riskOutcome not reported.Selective reporting (reporting bias)Unclear riskTime point for outcome assessment not defined.Other biasLow riskStudy sponsor: academic.[@CD008625-bbs2-0008]MethodsRandomized controlled trial.\
Follow up duration: not specified, probably while in hospital.ParticipantsLocation: Kolkata, India.\
Years: 1975.\
Participants: children and adults. No females participated.\
Number of participants: number randomized not specified, 76 evaluated.\
Cholera serogroup: not specified.\
Exclusion due to previous use of antibiotics: yes.\
Exclusion due to severity of symptoms: no.InterventionsPO Doxycycline: adults 200 mg single dose first day, 100 mg single dose second day; children 4 mg/kg single dose first day, 2 mg/kg single dose second day.\
PO Doxycycline: adults 200 mg single dose; children 4 mg/kg single dose.\
PO Doxycycline: adults 300 mg single dose; children 6 mg/kg single dose.\
PO Tetracycline: adults 500 mg four times per day; children 250 mg four times per day for 2 days.\
Resistance to intervention: not specified.OutcomesDiarrhoea duration in hours (defined as: time until the appearance of semisolid stools).\
Total fluid output in litres (definition not specified in study).\
Deaths (during follow up).\
Pathogen secretion duration in hours (definition not specified in study).\
Bacteriological failure (defined as: vibrios in stool after 48 hours from beginning of treatment).NotesEthics committee involved: not specified.\
consent requested and given from study participants: not specified.\
Type of hydration used in study: IV hydration, plain water.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNo description.Allocation concealment (selection bias)Unclear riskNo description.Blinding (performance bias and detection bias) All outcomesHigh riskPatients received different pills in different amounts.Incomplete outcome data (attrition bias) Diarrhoea durationUnclear riskNumber of patients randomized was not specified.Incomplete outcome data (attrition bias) Stool volumeUnclear riskNumber of patients randomized was not specified.Selective reporting (reporting bias)Unclear riskPrimary outcomes were not specified.Other biasUnclear riskStudy sponsor: academic, WHO, Pfizer supplied the Doxycycline.[@CD008625-bbs2-0009]MethodsRandomized controlled trial.\
Follow up duration: 5 days.ParticipantsLocation: Kolkata, India.\
Years: 1993 to 1994.\
Participants: adults. No females participated.\
Number of participants: 160 randomized, 111 evaluated.\
Cholera serogroup: O139.\
Exclusion due to previous use of antibiotics: yes.\
Exclusion due to severity of symptoms: no.InterventionsPO Doxycycline: 300 mg single dose.\
PO Norfloxacin: 400 mg twice per day for 3 days.\
PO Norfloxacin: 800 mg single dose.\
No treatment.\
Resistance to intervention: no resistance.OutcomesDiarrhoea duration in hours (defined as: time until passage of last unformed stool).\
Total fluid output in litres (definition not specified in study).\
Deaths (during follow up).\
Bacteriological failure (defined as: continued excretion of *V. cholerae* O139 in stool at day 3).NotesEthics committee involved: yes.\
consent requested and given from study participants: yes.\
Type of hydration used in study: IV hydration, ORS according to WHO recommendations.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandom number table.Allocation concealment (selection bias)Unclear riskNo description.Blinding (performance bias and detection bias) All outcomesHigh riskPatients received different pills in different amounts. Outcome assessor was blinded.Incomplete outcome data (attrition bias) Diarrhoea durationHigh risk11 to 14 patients out of 40 in each group were not evaluated for the outcome, reasons were not specified.Incomplete outcome data (attrition bias) Stool volumeHigh risk11 to 14 patients out of 40 in each group were not evaluated for the outcome, reasons were not specified.Selective reporting (reporting bias)Unclear riskPrimary outcomes were not specified.Other biasUnclear riskStudy sponsor: academic.[@CD008625-bbs2-0010]MethodsRandomized controlled trial.\
Follow up duration: 23 days.ParticipantsLocation: Ibadan, Nigeria.\
Years: not specified.\
Participants: age \> 10 years. Female participation not specified.\
Number of participants: number randomized not specified, 65 evaluated. Stool positive for *V. cholerae* required for inclusion.\
Cholera serogroup: O1.\
Exclusion due to previous use of antibiotics: yes.\
Exclusion due to severity of symptoms: no.InterventionsPO Fanasil: 2 g single dose. Followed by PO Dextrose (as placebo) twice per day for 3 days.\
PO Tetracyclime: 500 mg four times per day for 3 days.\
PO TMP‐SMX: (Trimetoprim 160 mg, Sulfametoxazol 900 mg) bid for 3 days.\
PO Dextrose (as placebo) bid for 3 days.\
Resistance to intervention: no resistance.OutcomesDiarrhoea duration in days (defined as: number of days until the patients ceased to pass more than 2 stools per day).\
Pathogen secretion duration in days (definition not specified in study).\
Clinical failure (defined as: more than 2 stools per day on day 2 or 3 of the study).\
Bacteriological failure (defined as: continued excretion of *V. cholerae* in stool at day 2 or 3 of study).NotesEthics committee involved: not specified.\
consent requested and given from study participants: not specified.\
Type of hydration used in study: IV hydration, ORS type not specified.\
Early stop: Placebo and Fanasil arms were stopped early.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNo description.Allocation concealment (selection bias)Unclear riskNo description.Blinding (performance bias and detection bias) All outcomesHigh riskBlinding broken, two arms were stopped early.Incomplete outcome data (attrition bias) Diarrhoea durationUnclear riskNumber of patients randomized was not specified.Incomplete outcome data (attrition bias) Stool volumeUnclear riskOutcome not reported.Selective reporting (reporting bias)High riskStudy outcomes were not specified at all in the methods section.Other biasLow riskStudy sponsor: academic.[@CD008625-bbs2-0011]MethodsRandomized controlled trial.\
Follow up duration: until faecal cultures were negative for three consecutive days.ParticipantsLocation: Teheran, Iran.\
Years: not specified.\
Participants: children and adults. Female participation not specified.\
Number of participants: number randomized not specified, 42 evaluated.\
Cholera serogroup: O1.\
Exclusion due to previous use of antibiotics: not specified.\
Exclusion due to severity of symptoms: not specified.InterventionsPO Chloramphenicol: 12.5 mg/kg (maximal dose 500 mg) four times per day for a minimum of 3 days (or until stool culture negative).\
PO Tetracycline: 10 mg/kg (maximal dose 500 mg) four times per day for a minimum of 3 days (or until stool culture negative).\
PO TMP‐SMX: (Trimetoprim 5 mg/kg maximal dose 195 mg, Sulfametoxazol 25 mg/kg maximal dose 800 mg) bid for a minimum of 3 days (or until stool culture negative).\
PO Dextrose (as placebo): twice per day for a minimum of 3 days (or until stool culture negative).\
Resistance to intervention: not specified.OutcomesBacteriological failure (defined as: stool positive for *V. cholerae* after day 2 of study).\
Bacteriological relapse (defined as: re‐appearance of *V. cholerae* in stool after initial eradication).NotesEthics committee involved: not specified.\
consent requested and given from study participants: not specified.\
Type of hydration used in study: IV hydration, ORS type not specified.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNo description.Allocation concealment (selection bias)Unclear riskNo description.Blinding (performance bias and detection bias) All outcomesHigh riskPatients received different pills in different amounts.Incomplete outcome data (attrition bias) Diarrhoea durationUnclear riskOutcome not reported.Incomplete outcome data (attrition bias) Stool volumeUnclear riskOutcome not reported.Selective reporting (reporting bias)Unclear riskTime point for outcome assessment not defined.Other biasLow riskStudy sponsor: academic.[@CD008625-bbs2-0012]MethodsRandomized controlled trial.\
Follow up duration: 4 days.ParticipantsLocation: Lima, Peru.\
Years: 1992 to 1993.\
Participants: adults aged 18 to 65 years; 35% females.\
Number of participants: 214 randomized, 202 evaluated.\
Cholera serogroup: O1.\
Exclusion due to previous use of antibiotics: yes.\
Exclusion due to severity of symptoms: no.InterventionsPO Ciprofloxacin: 250 mg once per day for 3 days. PO placebo matching Tetracycline.\
PO Tetracycline: 500 mg four times per day for 3 days. PO placebo matching Ciprofloxacin.\
Resistance to intervention: no resistance.OutcomesDiarrhoea duration in hours (defined as: time from initial administration of study drug to the last liquid stool passed).\
Stool volume in mL/kg (definition not specified in study).\
Clinical failure (defined as: diarrhoea on day 2 or 3 of study).\
Bacteriological failure (defined as: stool positive for *V. cholerae* after day 3 of study).NotesEthics committee involved: yes.\
consent requested and given from study participants: yes.\
Type of hydration used in study: IV hydration, ORS according to the WHO recommendations.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandom table with fixed blocks of ten.Allocation concealment (selection bias)Low riskEnvelopes labelled only with study number.Blinding (performance bias and detection bias) All outcomesLow riskDouble blind, identical looking pills.Incomplete outcome data (attrition bias) Diarrhoea durationLow riskOnly 7 out of 107 in the ciprofloxacin group and 5 out of 107 in the tetracycline group were not evaluated, reasons were not specified.Incomplete outcome data (attrition bias) Stool volumeLow riskOnly 7 out of 107 in the ciprofloxacin group and 5 out of 107 in the tetracycline group were not evaluated, reasons were not specified.Selective reporting (reporting bias)Unclear riskTime point for outcome assessment not defined.Other biasHigh riskStudy sponsor: Bayer.[@CD008625-bbs2-0013]MethodsRandomized controlled trial.\
Follow up duration: 5 days.ParticipantsLocation: Lima, Peru.\
Years: 1993.\
Participants: age \> 15 years; 32% females.\
Number of participants: number randomized not specified, 107 evaluated. Stool positive for *V. cholerae* required for inclusion.\
Cholera serogroup: O1.\
Exclusion due to previous use of antibiotics: yes.\
Exclusion due to severity of symptoms: no.InterventionsPO TMP‐SMX: (Trimetoprim 160 mg, Sulfametoxazol 800 mg) twice per day for 3 days.\
PO Tetracycline: 500 mg four times per day for 3 days.\
Resistance to intervention: 7% resistance to tetracycline.OutcomesDiarrhoea duration in hours (defined as: time from initial administration of study drug until stool output \< 400 mL/hour).\
Clinical failure (defined as: diarrhoea output above 400 mL/hour until discharged).\
Bacteriological failure (defined as: stool positive for *V. cholerae* 48 hours after completing treatment).NotesEthics committee involved: not specified.\
consent requested and given from study participants: yes.\
Type of hydration used in study: IV hydration, ORS type not specified.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNo description.Allocation concealment (selection bias)Unclear riskNo description.Blinding (performance bias and detection bias) All outcomesHigh riskPatients received different pills in different amounts.Incomplete outcome data (attrition bias) Diarrhoea durationUnclear riskNumber of patients randomized was not specified.Incomplete outcome data (attrition bias) Stool volumeUnclear riskNumber of patients randomized was not specified.Selective reporting (reporting bias)Unclear riskTime point for outcome assessment not defined.Other biasLow riskStudy sponsor: academic.[@CD008625-bbs2-0014]MethodsRandomized controlled trial.\
Follow up duration: until faecal cultures were negative for two consecutive days.ParticipantsLocation: Dhaka, Bangladesh.\
Years: 1993.\
Participants: adults. No females participated.\
Number of participants: 50 randomized, 43 evaluated. Stool positive for *V. cholerae* required for inclusion.\
Cholera serogroup: O139.\
Exclusion due to previous use of antibiotics: yes.\
Exclusion due to severity of symptoms: no.InterventionsPO Tetracycline: 500 mg four times per day for 3 days.\
PO placebo: four times per day for 3 days.\
Resistance to intervention: no resistance.OutcomesDiarrhoea duration in hours (defined as: time from initial administration of study drug until the end of the last 8‐hour period when a liquid stool has been passed).\
Stool volume in mL/kg (defined as: volume of stool in the 72 hours following the first administration of study drug).\
Pathogen secretion duration in days (definition not specified in study).\
Clinical failure (defined as: continuation of diarrhoea after 72 hours from initiation of study drug).\
Bacteriological failure (defined as: *V. cholerae* in stool after 72 hours from initiation of study drug).\
Clinical relapse (defined as: initial resolution of diarrhoea followed by passage of liquid stool anytime during the study).\
Bacteriological relapse (defined as: a positive culture following a negative stool sample that was obtained 72 hours after initiation of study drug).NotesEthics committee involved: not specified.\
consent requested and given from study participants: yes.\
Type of hydration used in study: IV hydration, rice‐based ORS.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer generated number list.Allocation concealment (selection bias)Low riskRandomization list kept with a researcher not involved in the study, pharmacist supplied drug by number.Blinding (performance bias and detection bias) All outcomesLow riskDouble blind, identical looking pills.Incomplete outcome data (attrition bias) Diarrhoea durationHigh risk4 out of 25 patients in the tetracycline group and 3 out of 25 in the placebo group were not evaluated, reasons were not specified.Incomplete outcome data (attrition bias) Stool volumeHigh risk4 out of 25 patients in the tetracycline group and 3 out of 25 in the placebo group were not evaluated, reasons were not specified.Selective reporting (reporting bias)Low riskStudy outcomes were clearly specified and reported.Other biasLow riskStudy sponsor: academic.[@CD008625-bbs2-0015]MethodsRandomized controlled trial.\
Follow up duration: not specified.ParticipantsLocation: Dhaka, Bangladesh.\
Years: not specified.\
Participants: adults; 46% females.\
Number of participants: 125 randomized, 118 evaluated. Stool positive for *V. cholerae* required for inclusion.\
Cholera serogroup: O1.\
Exclusion due to previous use of antibiotics: yes.\
Exclusion due to severity of symptoms: no.InterventionsPO Tetracycline: 1 g single dose.\
PO Tetracycline: 2 g single dose.\
PO Tetracycline: 500 mg four times per day for 1 day.\
No treatment.\
Resistance to intervention: no resistance.OutcomesDiarrhoea duration in hours (defined as: time until the end of the last 8 hour period in which liquid stool was passed).\
Stool volume in mL/kg (definition not specified in study).\
Pathogen secretion duration in days (definition not specified in study).\
Bacteriological failure (defined as: *V. cholerae* in stool after 48 or 72 hours).\
Clinical relapse (defined as: the return of liquid stool after passing solid stool).\
Bacteriological relapse (defined as: a patient who became bacteriologically negative for at least two consecutive days and was subsequently positive for *V. cholerae*).NotesEthics committee involved: not specified.\
consent requested and given from study participants: yes.\
Type of hydration used in study: IV hydration, ORS type not specified.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNo description.Allocation concealment (selection bias)Unclear riskNotes drawn from an envelope, not stated whether sealed and opaque.Blinding (performance bias and detection bias) All outcomesHigh riskControl arm was given no treatment.Incomplete outcome data (attrition bias) Diarrhoea durationLow riskOnly 5 out of 50 in the SD1 group and 2 out of 25 in the SD2 group were not evaluated, all patients in the tetracycline and control group were evaluated. Reasons for inclusion were not specified.Incomplete outcome data (attrition bias) Stool volumeLow riskOnly 5 out of 50 in the SD1 group and 2 out of 25 in the SD2 group were not evaluated, all patients in the tetracycline and control group were evaluated. Reasons for inclusion were not specified.Selective reporting (reporting bias)High riskStudy outcomes were not specified at all in the methods section.Other biasLow riskStudy sponsor: academic.[@CD008625-bbs2-0016]MethodsRandomized controlled trial.\
Follow up duration: 5 days minimum.ParticipantsLocation: Dhaka, Bangladesh.\
Years: 1991 to 1992.\
Participants: children aged 1 to 8 years. No females participated.\
Number of participants: 54 randomized, 48 evaluated. Stool positive for *V. cholerae* required for inclusion.\
Cholera serogroup: O1.\
Exclusion due to previous use of antibiotics: yes.\
Exclusion due to severity of symptoms: no.InterventionsPO Erythromycin: 12.5 mg/kg four times per day for 5 days.\
PO TMP‐SMX: (Trimetoprim 5 mg/kg, Sulfametoxazol 25 mg/kg) twice per day for 5 days.\
No treatment.\
Resistance to intervention: 23% resistance to Erythromycin and TMP‐SMX.OutcomesDiarrhoea duration in hours (defined as: time until the end of the last 8 hour period in which liquid stool was passed).\
Stool volume in mL/kg (definition not specified in study).\
Clinical failure (defined as: duration of diarrhoea which exceeded 72 hours).\
Bacteriological failure (defined as: *V. cholerae* in stool after day 3 of study).NotesEthics committee involved: not specified.\
consent requested and given from study participants: not specified.\
Type of hydration used in study: IV hydration, rice‐based ORS.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandom number table.Allocation concealment (selection bias)Low riskSealed envelopes containing the treatment code.Blinding (performance bias and detection bias) All outcomesHigh riskControl arm was given no treatment.Incomplete outcome data (attrition bias) Diarrhoea durationHigh risk6 out of 54 patients randomized were not evaluated, reasons were not specified.Incomplete outcome data (attrition bias) Stool volumeHigh risk6 out of 54 patients randomized were not evaluated, reasons were not specified.Selective reporting (reporting bias)Unclear riskPrimary outcomes were not specified.Other biasLow riskStudy sponsor: academic.[@CD008625-bbs2-0017]MethodsQuasi‐randomized controlled trial.\
Follow up duration: 14 days.ParticipantsLocation: Dacca, Pakistan.\
Years: 1966.\
Participants: children; 51% females.\
Number of participants: number randomized not specified, 78 evaluated.\
Cholera serogroup: O1.\
Exclusion due to previous use of antibiotics: not specified.\
Exclusion due to severity of symptoms: not specified.InterventionsPO Furazolidone: 1.25 mg/kg four times per day for 7 days.\
PO Tetracycline: 2.5 mg/kg four times per day for 7 days.\
PO Tetracycline: 7.75 to 15.25 mg/kg four times per day for 7 days.\
No treatment.\
Resistance to intervention: not specified.OutcomesDiarrhoea duration in 8 hour periods (defined as: time until the end of the last 8 hour period in which liquid stool was passed).\
Stool volume in litres (definition not specified in study).\
Pathogen secretion duration in days (definition not specified in study).NotesEthics committee involved: not specified.\
consent requested and given from study participants: not specified.\
Type of hydration used in study: IV hydration only.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High riskAccording to day of admission.Allocation concealment (selection bias)High riskTreatment allocated by day of week.Blinding (performance bias and detection bias) All outcomesHigh riskControl arm was given no treatment.Incomplete outcome data (attrition bias) Diarrhoea durationUnclear riskNumber of patients randomized was not specified.Incomplete outcome data (attrition bias) Stool volumeUnclear riskNumber of patients randomized was not specified.Selective reporting (reporting bias)High riskStudy outcomes were not specified at all in the methods section.Other biasLow riskStudy sponsor: academic.[@CD008625-bbs2-0018]MethodsRandomized controlled trial.\
Follow up duration: 7 days.ParticipantsLocation: Delhi, India.\
Years: 2006 to 2007.\
Participants: Children aged 2 to 12 years; 43% female.\
Number of participants: 407 randomized, 180 evaluated. Stool positive for *V .cholerae* required for inclusion.\
Cholera serogroup: not specified.\
Exclusion due to previous use of antibiotics: yes.\
Exclusion due to severity of symptoms: yes.InterventionsPO Azithromycin: 20 mg/kg single dose.\
PO Ciprofloxacin: 20 mg/kg single dose.\
Resistance to intervention: 0.6% resistance to Ciprofloxacin. Resistance to Azithromycin not specified.OutcomesDiarrhoea duration hours (defined as: time from entry to study until resolution of diarrhoea).\
Pathogen secretion duration in hours (definition not specified in study).\
Clinical failure (defined as: continuation of diarrhoea after 72 hours from the beginning of therapy).\
Bacteriological failure (defined as: *V. cholerae* in stool on day 3 of the study).\
Clinical relapse (defined as: cessation of diarrhoea for one day or longer, followed by the return of diarrhoea).\
Bacteriological relapse (defined as: positive stool culture following a negative one).NotesEthics committee involved: yes.\
consent requested and given from study participants: yes.\
Type of hydration used in study: IV hydration, ORS (type unspecified).***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandom number table.Allocation concealment (selection bias)Low riskIdentical sealed envelopes, opened only after enrolment.Blinding (performance bias and detection bias) All outcomesHigh riskDifferent pills, both given single doseIncomplete outcome data (attrition bias) Diarrhoea durationHigh risk114 out of 205 in the azithromycin group and 113 out of 202 in the ciprofloxacin group were not evaluated, reasons were not specified.Incomplete outcome data (attrition bias) Stool volumeUnclear riskOutcome not reported.Selective reporting (reporting bias)Unclear riskTime point for outcome assessment not defined.Other biasLow riskNo sponsor.[@CD008625-bbs2-0019]MethodsRandomized controlled trial.\
Follow up duration: 3 days.ParticipantsLocation: Dhaka, Bangladesh.\
Years: not specified.\
Participants: adults. No females participated.\
Number of participants: 64 randomized, 63 evaluated.\
Cholera serogroup: O139.\
Exclusion due to previous use of antibiotics: yes.\
Exclusion due to severity of symptoms: no.InterventionsPO Tetracycline: 500 mg four times per day for 3 days.\
PO Erythromycin: 500 mg four times per day for 3 days.\
PO Ciprofloxacin: 1 g single dose.\
PO Doxycycline: 300 mg single dose.\
Resistance to intervention: not specified.OutcomesDiarrhoea duration in hours (defined as: time from administration of study drug until the end of the last 8 hour period in which liquid stool was passed).\
Stool volume in mL/kg (definition not specified in study).NotesEthics committee involved: not specified.\
consent requested and given from study participants: yes.\
Type of hydration used in study: IV hydration, ORS type not specified.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNo description.Allocation concealment (selection bias)Unclear riskNo description.Blinding (performance bias and detection bias) All outcomesHigh riskPatients received different pills in different amounts.Incomplete outcome data (attrition bias) Diarrhoea durationLow riskAll patients, with the exception of 1 out of 16 in the erythromycin group, were evaluated.Incomplete outcome data (attrition bias) Stool volumeLow riskAll patients, with the exception of 1 out of 16 in the erythromycin group, were evaluated.Selective reporting (reporting bias)High riskStudy outcomes were not specified at all in the methods section.Other biasLow riskStudy sponsor: academic.[@CD008625-bbs2-0020]MethodsRandomized controlled trial.\
Follow up duration: 3 to 5 days.ParticipantsLocation: Dhaka, Bangladesh.\
Years: 1992.\
Participants: adults. No females participated.\
Number of participants: 75 randomized, 72 evaluated.\
Cholera serogroup: O1.\
Exclusion due to previous use of antibiotics: yes.\
Exclusion due to severity of symptoms: no.InterventionsPO Ciproflixacin: 500 mg twice per day for 3 days.\
PO Erythromycin: 500 mg four times per day for 3 days.\
PO Nalidixic acid: 500 mg four times per day for 3 days.\
PO Pivmecillinam: 400 mg four times per day for 3 days.\
PO Tetracycline: 500 mg four times per day for 3 days.\
Resistance to intervention: 75% resistance to Tetracycline in all arms; 100% resistance to Tetracycline in the Tetracycline arm.OutcomesStool volume in mL/kg (definition not specified in study).\
Clinical failure (defined as: continuation of diarrhoea after 72 hours of treatment).\
Bacteriological failure (defined as: *V. cholerae* in stool after day 2 or 3 of study).NotesEthics committee involved: not specified.\
consent requested and given from study participants: yes.\
Type of hydration used in study: IV hydration, ORS type not specified.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskBlock randomized method with a block size of 10.Allocation concealment (selection bias)Low riskSealed envelopes.Blinding (performance bias and detection bias) All outcomesHigh riskPatients received different pills in different amounts.Incomplete outcome data (attrition bias) Diarrhoea durationUnclear riskOutcome not reported.Incomplete outcome data (attrition bias) Stool volumeLow riskAll patients, with the exception of 3 out of 15 in the tetracycline group, were evaluated.Selective reporting (reporting bias)High riskStudy outcomes were not specified at all in the methods section.Other biasLow riskStudy sponsor: academic.[@CD008625-bbs2-0021]MethodsRandomized controlled trial.\
Follow up duration: 12 days.ParticipantsLocation: Dhaka and rural Matlab district, Bangladesh.\
Years: 1993 to 1995.\
Participants: adults. No females participated.\
Number of participants: 272 randomized, 260 evaluated.\
Cholera serogroup: O1, O139.\
Exclusion due to previous use of antibiotics: yes.\
Exclusion due to severity of symptoms: no.InterventionsO1 group:\
PO Ciproflixacin: 1 g single dose. PO placebo matching Doxycycline.\
PO Doxycycline: 300 mg single dose. PO placebo matching Ciproflixacin.\
O139 group:\
PO Ciproflixacin: 1 g single dose. PO placebo matching Doxycycline.\
PO Doxycycline: 300 mg single dose. PO placebo matching Ciproflixacin.\
Resistance to intervention: one O1 strain isolated which was resistant to Doxycycline.OutcomesStool volume in mL/kg (definition not specified in study).\
Clinical failure (defined as: continuation of diarrhoea after 48 or 72 hours of treatment).\
Bacteriological failure (defined as: *V. cholerae* in stool after day 2 or 3 of study).NotesEthics committee involved: yes.\
consent requested and given from study participants: yes.\
Type of hydration used in study: IV hydration, ORS type not specified.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer generated list, randomization blocks of 10.Allocation concealment (selection bias)Low riskPatients were consecutively assigned numbers, perilously allocated to treatment.Blinding (performance bias and detection bias) All outcomesLow riskDouble blind, identical looking pills.Incomplete outcome data (attrition bias) Diarrhoea durationLow riskOnly 12 out of 272 were not evaluated, reasons were not specified.Incomplete outcome data (attrition bias) Stool volumeLow riskOnly 12 out of 272 were not evaluated, reasons were not specified.Selective reporting (reporting bias)Low riskStudy outcomes were clearly specified and reported.Other biasHigh riskStudy sponsor: academic, Bayer, Pfizer supplied drugs.[@CD008625-bbs2-0022]MethodsRandomized controlled trial.\
Follow up duration: 12 days.ParticipantsLocation: Dhaka and rural Matlab district, Bangladesh.\
Years: 1999.\
Participants: children aged 1 to 15 years. No females participated.\
Number of participants: 128 randomized, 123 evaluated.\
Cholera serogroup: O1, O139.\
Exclusion due to previous use of antibiotics: yes.\
Exclusion due to severity of symptoms: no.InterventionsPO Azithromycin: 20 mg/kg (maximal individual dose: 1 g) single dose. PO placebo matching Erithromycin.\
PO Erithromycin: 12.5 mg/kg (maximal individual dose: 500 mg) four times per day PO placebo matching Azithromycin.\
Resistance to intervention: no resistance.OutcomesDiarrhoea duration in hours (defined as: interval between administration of study drug to the end of the last 6 hours period in which patient passed a watery stool).\
Stool volume in mL/kg (definition not specified in study).\
Clinical failure (defined as: continuation of diarrhoea after 48 or 72 hours of treatment).\
Bacteriological failure (defined as: *V. cholerae* in stool after day 2 of study).\
Clinical relapse (defined as: re‐appearance of diarrhoea after discharge).\
Bacteriological relapse (defined as: positive culture on day 7 after discharge).NotesEthics committee involved: yes.\
consent requested and given from study participants: yes.\
Type of hydration used in study: IV hydration, ORS type not specified.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated list using a block randomization method with a block size of four, stratified by site.Allocation concealment (selection bias)Low riskPatients were consecutively assigned a study number and provided study treatment that had been randomly pre‐assigned to that number. List kept centrally.Blinding (performance bias and detection bias) All outcomesLow riskDouble blind, identical looking pills. Outcome assessor also blinded.Incomplete outcome data (attrition bias) Diarrhoea durationLow riskOnly 2 out of 65 in the azithromycin group and 3 out of 63 in the erythromycin group were not evaluated, reasons were not specified.Incomplete outcome data (attrition bias) Stool volumeLow riskOnly 2 out of 65 in the azithromycin group and 3 out of 63 in the erythromycin group were not evaluated, reasons were not specified.Selective reporting (reporting bias)Low riskStudy outcomes were clearly specified and reported.Other biasHigh riskStudy sponsor: academic, Pfizer.[@CD008625-bbs2-0023]MethodsRandomized controlled trial.\
Follow up duration: 8 days.ParticipantsLocation: Godoume, Cote d\'Ivoire.\
Years: 1970.\
Participants: children and adults. Female participation not specified.\
Number of participants: number randomized not specified, 37 evaluated.\
Cholera serogroup: O1.\
Exclusion due to previous use of antibiotics: not specified.\
Exclusion due to severity of symptoms: no.InterventionsPO Sulfometoxine: dose according to age, adult dose 2 g single dose.\
PO Pyridoxine as placebo: dose according to age single dose.\
Resistance to intervention: not stated.OutcomesClinical failure (defined as: no definitive disappearance of diarrhoea on day 3 or 5 of study).NotesEthics committee involved: not specified.\
Consent requested and given from study participants: not specified.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNo descriptionAllocation concealment (selection bias)Unclear riskNo descriptionBlinding (performance bias and detection bias) All outcomesHigh riskStated as double blind, but patients received different pills in different amounts.Incomplete outcome data (attrition bias) Diarrhoea durationUnclear riskOutcome not reported.Incomplete outcome data (attrition bias) Stool volumeUnclear riskOutcome not reported.Selective reporting (reporting bias)High riskStudy reported on different outcomes in the results than previously specified in the methods.Other biasUnclear riskEthics committee involved: not specified.\
Consent requested and given from study participants: not specified.\
Type of hydration used in study: IV hydration, ORS type not specified.[@CD008625-bbs2-0024]MethodsQuasi‐randomized controlled trial.\
Follow up duration: until stools were negative for *V. cholerae* for 3 consecutive days.ParticipantsLocation: Dacca, Pakistan.\
Years: 1964 to 1966.\
Participants: adults; 34% females.\
Number of participants: number randomized not specified, 313 evaluated. Stool positive for *V.cholerae* required for inclusion.\
Cholera serogroup: Not specified (probably O1).\
Exclusion due to previous use of antibiotics: yes.\
Exclusion due to severity of symptoms: no.InterventionsPO Tetracycline: 250, 500 or 750 mg four times per day for 2, 3 or 4 days.\
PO Chloramphenicol: 250, 500 or 750 mg four times per day for 2 or 3 days.\
PO Streptomycin: 1 g four times per day for 2 or 3 days.\
PO Paromomycin: 250 or 500 mg four times per day for 2 or 3 days.\
No treatment.\
Resistance to intervention: no resistance.OutcomesDiarrhoea duration in 8 hour periods (defined as: time until the end of the last 8 hour period in which liquid stool was passed).\
Stool volume in litres (definition not specified in study).\
Deaths during study (definition not specified in study).\
Pathogen secretion duration in days (definition not specified in study).\
Clinical failure (defined as: diarrhoea that lasted more than 4 days in treated patients).\
Clinical relapse (defined as: passing formed stool and subsequently passing watery stool enough to require resumption of IV hydration).\
Bacteriological relapse (defined as: stool negative for at least one day and than positive again).NotesEthics committee involved: not specified.\
consent requested and given from study participants: not specified.\
Type of hydration used in study: IV hydration only.\
Early stop: Streptomycin and Paromomycin arms were stopped early.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High riskRandomization according to day of admission.Allocation concealment (selection bias)High riskTreatment allocation according to day of admission.Blinding (performance bias and detection bias) All outcomesHigh riskPatients received different pills in different amounts and durations.Incomplete outcome data (attrition bias) Diarrhoea durationUnclear riskNumber of patients randomized was not specified.Incomplete outcome data (attrition bias) Stool volumeUnclear riskNumber of patients randomized was not specified.Selective reporting (reporting bias)Unclear riskPrimary outcomes were not specified.Other biasLow riskNo sponsor.[@CD008625-bbs2-0025]MethodsQuasi‐randomized controlled trial.\
Follow up duration: until stools were negative for *V. cholerae* for 3 consecutive days.ParticipantsLocation: Dacca, Pakistan.\
Years: 1964 to 1966.\
Participants: children aged 6 weeks to 10 years; 46% females.\
Number of participants: 243 randomized, 238 evaluated. Stool positive for *V.cholerae* required for inclusion.\
Cholera serogroup: Not specified (probably O1).\
Exclusion due to previous use of antibiotics: not specified.\
Exclusion due to severity of symptoms: no.InterventionsPO Tetracycline: 125 or 250 mg four times per day for 2, 3 or 4 days.\
PO Chloramphenicol: 125, 250 or 500 mg four times per day for 2 or 3 days.\
PO Streptomycin: 500 mg four times per day for 2 or 3 days.\
PO Paromomycin: 125 or 250 mg four times per day for 2 or 3 days.\
No treatment.\
Resistance to intervention: not specified.OutcomesDiarrhoea duration in 8 hour periods (defined as: time until the end of the last 8 hour period in which liquid stool was passed).\
Stool volume in litres (definition not specified in study).\
Pathogen secretion duration in days (definition not specified in study).\
Clinical failure (defined as: diarrhoea that lasted more than 4 days in treated patients).\
Clinical relapse (defined as: passing formed stool and subsequently passing watery stool enough to require resumption of IV hydration).\
Bacteriological relapse (defined as: stool negative for at least 1 day and then positive again).NotesEthics committee involved: not specified.\
consent requested and given from study participants: not specified.\
Type of hydration used in study: IV hydration only.\
Early stop: Streptomycin and Paromomycin arms were stopped early.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High riskRandomization according to day of admission.Allocation concealment (selection bias)High riskTreatment allocation according to day of admission.Blinding (performance bias and detection bias) All outcomesHigh riskPatients received different pills in different amounts and durations.Incomplete outcome data (attrition bias) Diarrhoea durationLow riskOnly 5 out of 243 were not evaluated, reasons were not specified.Incomplete outcome data (attrition bias) Stool volumeLow riskOnly 5 out of 243 were not evaluated, reasons were not specified.Selective reporting (reporting bias)Unclear riskPrimary outcomes were not specified.Other biasLow riskNo sponsor.[@CD008625-bbs2-0026]MethodsRandomized controlled trial.\
Follow up duration: 10 to 15 days.ParticipantsLocation: Nohnburi, Thailand.\
Years: 1986 to 1987.\
Participants: adults; 51% females.\
Number of participants: 450 randomized, 47 evaluated.\
Cholera serogroup: O1.\
Exclusion due to previous use of antibiotics: no.\
Exclusion due to severity of symptoms: yes.InterventionsPO Norfloxacine: 400 mg twice per day for 3 days.\
PO TMP‐SMX: (Trimetoprim 160 mg, Sulfametoxazol 800 mg) twice per day for 3 days.\
PO placebo: twice per day for 3 days.\
Resistance to intervention: 2% resistance to TMP‐SMX.OutcomesDuration of diarrhoea in hours (defined as: time from start of treatment until disappearance of watery stools and no more than 3 stools per day).\
Bacteriological failure (defined as: positive stool culture on day 4 of study).NotesEthics committee involved: not specified.\
consent requested and given from study participants: yes.\
Type of hydration used in study: IV hydration, ORS type not specified.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNo description.Allocation concealment (selection bias)Unclear riskNo description.Blinding (performance bias and detection bias) All outcomesLow riskDouble blind, identical looking pills.Incomplete outcome data (attrition bias) Diarrhoea durationHigh riskOnly a few of the patients randomized (14 to18 out of 150 in each group) were evaluated, reasons were not specified.Incomplete outcome data (attrition bias) Stool volumeUnclear riskOutcome not reported.Selective reporting (reporting bias)Unclear riskPrimary outcomes were not specified.Other biasHigh riskStudy sponsor: academic, Astra Alab.[@CD008625-bbs2-0027]MethodsRandomized controlled trial.\
Follow up duration: 5 days minimum.ParticipantsLocation: Angoda, Sri Lanka.\
Years: not specified.\
Participants: adults; 45% females.\
Number of participants: 20 randomized and evaluated. Stool positive for *V .cholerae* required for inclusion.\
Cholera serogroup: not specified (most probably O1).\
Exclusion due to previous use of antibiotics: no.\
Exclusion due to severity of symptoms: no.InterventionsPO Sulphadoxine: 2 g single dose.\
PO Tetracycline: 500 mg four times per day for 3 days.\
Resistance to intervention: no resistance.OutcomesStool volume in litres (definition not specified in study).\
Bacteriological failure (defined as: *V. cholerae* in stool on day 2 or 3 of study).NotesEthics committee involved: not specified.\
consent requested and given from study participants: not specified.\
Type of hydration used in study: IV hydration, ORS type not specified.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskTable of random numbers.Allocation concealment (selection bias)Unclear riskNo description.Blinding (performance bias and detection bias) All outcomesHigh riskPatients received different pills in different amounts. Outcome assessor was blinded.Incomplete outcome data (attrition bias) Diarrhoea durationUnclear riskOutcome not reported.Incomplete outcome data (attrition bias) Stool volumeLow riskAll patients randomized were evaluated.Selective reporting (reporting bias)Unclear riskTime point for outcome assessment not defined.Other biasLow riskNo sponsor.[@CD008625-bbs2-0028]MethodsRandomized controlled trial.\
Follow up duration: not specified.ParticipantsLocation: Bangkok, Thailand.\
Years: 1994 to 1996.\
Participants: children and adults; 48% females.\
Number of participants: number randomized not specified, 25 evaluated.\
Cholera serogroup: O1, O139.\
Exclusion due to previous use of antibiotics: yes.\
Exclusion due to severity of symptoms: yes.InterventionsPO Tetracycline: adults 500 mg; children 12.5 mg/kg four times per day for 3 days.\
PO Norfloxacine: adults 400 mg; children 7.5 mg/kg twice per day for 3 days.\
Resistance to intervention: no resistance.OutcomesDuration of diarrhoea (definition not specified in study).\
Deaths (during study).\
Pathogen secretion duration in days (definition not specified in study).NotesEthics committee involved: not specified.\
consent requested and given from study participants: not specified.\
Type of hydration used in study: IV hydration, ORS type not specified.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNo description.Allocation concealment (selection bias)Unclear riskNo description.Blinding (performance bias and detection bias) All outcomesHigh riskPatients received different pills in different amounts.Incomplete outcome data (attrition bias) Diarrhoea durationUnclear riskNumber of patients randomized was not specified.Incomplete outcome data (attrition bias) Stool volumeUnclear riskOutcome not reported.Selective reporting (reporting bias)Unclear riskTime point for outcome assessment not defined.Other biasLow riskNo sponsor.[@CD008625-bbs2-0029]MethodsRandomized controlled trial.\
Follow up duration: not specified.ParticipantsLocation: Kolkata, India.\
Years: 1967.\
Participants: adults. No females participated.\
Number of participants: 65 randomized, 49 evaluated.\
Cholera serogroup: O1.\
Exclusion due to previous use of antibiotics: yes.\
Exclusion due to severity of symptoms: no.InterventionsPO Tetracycline: adults 500 mg four times per day for 2 days.\
PO Furazolidone: 200 mg four times per day for 3 days.\
PO Furazolidone: 400 mg once per day for 3 days.\
No treatment.\
Resistance to intervention: no resistance.OutcomesDuration of diarrhoea (defined as: time from entry to study until the last passage of any liquid stool). \
Stool volume in mL/kg (definition not specified in study).\
Deaths (during study).\
Pathogen secretion duration in hours (defined as: time from entry until the last positive stool culture was obtained).\
Clinical relapse (defined as: recurrence of diarrhoea after termination of therapy).\
Bacteriological relapse (defined as: positive culture after 3 days with negative cultures).NotesEthics committee involved: not specified.\
consent requested and given from study participants: not specified.\
Type of hydration used in study: IV hydration, water, green coconut water.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNo description.Allocation concealment (selection bias)Unclear riskNo description.Blinding (performance bias and detection bias) All outcomesHigh riskControl arm was given no treatmentIncomplete outcome data (attrition bias) Diarrhoea durationHigh riskNumber of patients randomized to each group was not specified. Data was evaluated for only 49 patients out of a total of 65 patients participating.Incomplete outcome data (attrition bias) Stool volumeHigh riskNumber of patients randomized to each group was not specified. Data was evaluated for only 49 patients out of a total of 65 patients participating.Selective reporting (reporting bias)High riskStudy outcomes were not specified at all in the methods section.Other biasLow riskStudy sponsor: academic.[@CD008625-bbs2-0030]MethodsRandomized controlled trial.\
Follow up duration: 7 days minimum.ParticipantsLocation: Dhaka, Bangladesh.\
Years: not specified.\
Participants: adults. Female participation not specified.\
Number of participants: 114 randomized, 87 evaluated. Stool positive for *V .cholerae* required for inclusion.\
Cholera serogroup: not specified.\
Exclusion due to previous use of antibiotics: yes.\
Exclusion due to severity of symptoms: yes.InterventionsPO Tetracycline: 1 g single dose.\
PO Furazolidone: 400 mg single dose.\
PO placebo: 2 tabs single dose.\
Resistance to intervention: 13% resistance to Tetracycline; 22% resistance to Furazolidone.OutcomesDiarrhoea duration hours (defined as: time until the end of the last 8 hour period in which liquid stool was passed).\
Stool volume in litres (definition not specified in study).\
Clinical failure (defined as: continuation of diarrhoea on day 4 or after).\
Bacteriological failure (defined as: positive stool cultures 48 or 96 hours after treatment).\
Clinical relapse (defined as: cure on day 4 with subsequent relapse).\
Bacteriological relapse (defined as: stool positive for *V cholerae* on day 6).NotesEthics committee involved: yes.\
consent requested and given from study participants: yes.\
Type of hydration used in study: IV hydration, water.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskTable of random numbers.Allocation concealment (selection bias)Low riskAssuming the table was code: bottles containing the drugs numerically coded, code kept in New York and opened only after the study had been completed.Blinding (performance bias and detection bias) All outcomesLow riskDouble blind, identical looking pills.Incomplete outcome data (attrition bias) Diarrhoea durationHigh risk27 out of 114 were not evaluated, reasons were not specified.Incomplete outcome data (attrition bias) Stool volumeHigh risk27 out of 114 were not evaluated, reasons were not specified.Selective reporting (reporting bias)Unclear riskPrimary outcomes were not specified.Other biasHigh riskStudy sponsor: Norwich Eaton Pharmaceuticals.[@CD008625-bbs2-0031]MethodsRandomized controlled trial.\
Follow up duration: not specified.ParticipantsLocation: Dhaka, Bangladesh.\
Years: 1985 to 1987.\
Participants: children aged 1 month to 14 years; 28% females.\
Number of participants: number randomized not specified, 106 evaluated. Stool positive for *V .cholerae* required for inclusion.\
Cholera serogroup: not specified.\
Exclusion due to previous use of antibiotics: not specified.\
Exclusion due to severity of symptoms: yes.InterventionsPO Furazolidone: 7 mg/kg single dose.\
PO Furazolidone: 1.75 mg/kg four times per day for 3 days.\
PO placebo: single dose.\
PO placebo: four times per day for 3 days.\
Resistance to intervention: 12% resistance to Furazolidone on the single dose arm; no resistance to Furazolidone on the multiple dose arm.OutcomesDiarrhoea duration hours (defined as: time until the end of the last 8 hour period in which liquid stool was passed).\
Stool volume in litres (definition not specified in study).\
Pathogen secretion duration in days (definition not specified in study).\
Clinical failure (defined as: continuation of diarrhoea beyond 72 hours from the start of treatment).\
Bacteriological failure (defined as: stool cultures positive for *V. cholerae* on days 2, 3 or 4 after the start of treatment).NotesEthics committee involved: not specified.\
consent requested and given from study participants: yes.\
Type of hydration used in study: IV hydration, water.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated list of random numbers.Allocation concealment (selection bias)Unclear riskNo description.Blinding (performance bias and detection bias) All outcomesLow riskDouble blind, identical looking pills.Incomplete outcome data (attrition bias) Diarrhoea durationUnclear riskNumber of patients randomized was not specified.Incomplete outcome data (attrition bias) Stool volumeUnclear riskNumber of patients randomized was not specified.Selective reporting (reporting bias)Unclear riskPrimary outcomes were not specified.Other biasHigh riskStudy sponsor: Norwich‐Eaton Pharmaceuticals, Inc.[@CD008625-bbs2-0032]MethodsQuasi‐randomized controlled trial.\
Follow up duration: not specified.ParticipantsLocation: Dhaka, Bangladesh.\
Years: 1974 to 1975.\
Participants: children and adults. Female participation not specified.\
Number of participants: number randomized not specified, 51 evaluated.\
Cholera serogroup: not specified.\
Exclusion due to previous use of antibiotics: yes.\
Exclusion due to severity of symptoms: no.InterventionsPO Doxycycline: adults 100 mg; children 2 mg/kg twice per day on the first day, once per day on the next 3 days.\
PO Tetracycline: 5 mg/kg four times per day for 4 days.\
PO placebo: administration manner not specified.\
Resistance to interventionOutcomesDiarrhoea duration hours (definition not specified in study).\
Stool volume in litres (definition not specified in study).\
Deaths (during study).\
Pathogen secretion duration in days (definition not specified in study).NotesEthics committee involved: not specified.\
consent requested and given from study participants: not specified.\
Type of hydration used in study: IV hydration, ORS type not specified.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High riskCards pre‐arranged consecutively.Allocation concealment (selection bias)High riskCards pre‐arranged consecutively; codes held in sealed envelopes.Blinding (performance bias and detection bias) All outcomesHigh riskPlacebo was used only to match Doxycycline, not Tetracycline.Incomplete outcome data (attrition bias) Diarrhoea durationUnclear riskNumber of patients randomized was not specified.Incomplete outcome data (attrition bias) Stool volumeUnclear riskNumber of patients randomized was not specified.Selective reporting (reporting bias)Unclear riskPrimary outcomes were not specified.Other biasUnclear riskStudy sponsor: academic, Pfizer supplied placebo.[@CD008625-bbs2-0033]MethodsRandomized controlled trial.\
Follow up duration: 4 days.ParticipantsLocation: Dhaka, Bangladesh.\
Years: not specified.\
Participants: children aged 1 to 5 years. Female participation not specified.\
Number of participants: 184 randomized and evaluated. Stool positive for *V .cholerae* required for inclusion.\
Cholera serogroup: O1.\
Exclusion due to previous use of antibiotics: yes.\
Exclusion due to severity of symptoms: no.InterventionsPO Erythromycin: 12.5 mg/kg four times per day for 3 days.\
PO Ampicillin: 12.5 mg/kg four times per day for 3 days.\
PO Tetracycline: 6.5 mg/kg four times per day for 3 days.\
PO placebo: four times per day for 3 days.\
Resistance to intervention: 1% resistance to Ampicillin; 2% resistance to Erythromycin; and 24% resistance to Tetracycline.OutcomesStool volume in litres (definition not specified in study).\
Bacteriological failure (defined as: stool cultures positive for *V. cholerae* 48 hours after the start of treatment).NotesEthics committee involved: not specified.\
consent requested and given from study participants: yes.\
Type of hydration used in study: IV hydration, rice‐based ORS.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNo description.Allocation concealment (selection bias)Unclear riskNo description.Blinding (performance bias and detection bias) All outcomesLow riskDouble blind, identical looking pills.Incomplete outcome data (attrition bias) Diarrhoea durationUnclear riskOutcome not reported.Incomplete outcome data (attrition bias) Stool volumeLow riskAll patients randomized were evaluated.Selective reporting (reporting bias)High riskStudy outcomes were not specified at all in the methods section.Other biasLow riskStudy sponsor: academic.[@CD008625-bbs2-0034]MethodsRandomized controlled trial.\
Follow up duration: until stools were negative for *V. cholerae* for 2 consecutive days.ParticipantsLocation: Dhaka, Bangladesh.\
Years: not specified.\
Participants: children and adults. No females participated.\
Number of participants: 74 randomized, 65 evaluated. Stool positive for *V .cholerae* required for inclusion.\
Cholera serogroup: O1.\
Exclusion due to previous use of antibiotics: yes.\
Exclusion due to severity of symptoms: no.InterventionsPO Doxycycline: adults 200 mg; children 4 mg/kg single dose.\
PO Doxycycline: adults 100 mg; children 2 mg/kg twice per day on the first day, once per day on the next 3 days.\
Resistance to intervention: not specified.OutcomesStool weight in mg/kg (definition not specified in study).NotesEthics committee involved: not specified.\
consent requested and given from study participants: yes.\
Type of hydration used in study: IV hydration, water.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskPredetermined list of random numbers.Allocation concealment (selection bias)Unclear riskNo description.Blinding (performance bias and detection bias) All outcomesHigh riskPatients received different amounts of pills.Incomplete outcome data (attrition bias) Diarrhoea durationHigh risk9 out of 74 patients randomized were not evaluated, reasons were not specified.Incomplete outcome data (attrition bias) Stool volumeUnclear riskOutcome not reported.Selective reporting (reporting bias)Unclear riskPrimary outcomes were not specified.Other biasUnclear riskStudy sponsor: academic. Pfizer Laboratory measured serum levels.[@CD008625-bbs2-0035]MethodsRandomized controlled trial.\
Follow up duration: 6 weeks.ParticipantsLocation: Dhaka and rural Matlab district, Bangladesh.\
Years: 2001 to 2002.\
Participants: children aged 2 to 15 years. Female participation not specified.\
Number of participants: 180 randomized, 162 evaluated. Stool positive for *V .cholerae* required for inclusion.\
Cholera serogroup: O1, O139.\
Exclusion due to previous use of antibiotics: yes.\
Exclusion due to severity of symptoms: no.InterventionsPO Ciprofloxacin: 20 mg/kg (maximal dose 750 mg) single dose.\
PO Erythromycin: 12.5 mg/kg (maximal dose 500 mg) four times per day for 3 days.\
Resistance to intervention: no resistance.OutcomesDiarrhoea duration in hours (defined as: time from the administration of study drug until the end of the last 6 hour period without diarrhoea).\
Stool volume in litres (definition not specified in study).\
Clinical failure (defined as: continuation of diarrhoea after 48 hours from the administration of study drug).\
Bacteriological failure (defined as: stool cultures positive for *V. cholerae* after day 2 of study).NotesEthics committee involved: yes.\
consent requested and given from study participants: yes.\
Type of hydration used in study: IV hydration, rice‐based ORS.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated list prepared by individuals not otherwise involved in the study with a block size of eight.Allocation concealment (selection bias)Low riskSealed boxes opened after a patient had been enrolled in the study and assigned a study number.Blinding (performance bias and detection bias) All outcomesHigh riskPatients in different arms received different amounts of medication.Incomplete outcome data (attrition bias) Diarrhoea durationLow riskOnly 12 out of 90 patients in the ciprofloxacin group and 6 out of 90 in the erythromycin group were not evaluated, reasons were not specified.Incomplete outcome data (attrition bias) Stool volumeLow riskOnly 12 out of 90 patients in the ciprofloxacin group and 6 out of 90 in the erythromycin group were not evaluated, reasons were not specified.Selective reporting (reporting bias)Low riskStudy outcomes were clearly specified and reported.Other biasHigh riskStudy sponsor: academic, Bayer AG.[@CD008625-bbs2-0036]MethodsRandomized controlled trial.\
Follow up duration: 12 to 15 days.ParticipantsLocation: Dhaka, Bangladesh.\
Years: 2002 to 2004.\
Participants: adults. No females participated.\
Number of participants: 198 randomized, 195 evaluated. Stool positive for *V .cholerae* required for inclusion.\
Cholera serogroup: O1, O139.\
Exclusion due to previous use of antibiotics: yes.\
Exclusion due to severity of symptoms: no.InterventionsPO Azithromycin: 1 g single dose; PO placebo matching Ciprofloxacin.\
PO Ciprofloxacin: 1 g single dose; PO placebo matching Azithromycin.\
Resistance to intervention: no resistance.OutcomesDiarrhoea duration hours (defined as: time from administration of study drug until the end of the last 6 hours period without diarrhoea).\
Stool volume in mL/kg (definition not specified in study).\
Clinical failure (defined as: continuation of diarrhoea after 48 hours from administration of study drug).\
Bacteriological failure (defined as: stool cultures positive for *V. cholerae* after 48 hours from administration of study drug).NotesEthics committee involved: yes.\
consent requested and given from study participants: yes.\
Type of hydration used in study: IV hydration, rice‐based ORS.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskBlock randomizations with a block of six done by an independent researcher who was not involved in the study.Allocation concealment (selection bias)Low riskDrugs and placebo were put in identical bottles with sequential numbers according to the randomized list .Blinding (performance bias and detection bias) All outcomesLow riskDouble blind, identical looking pills.Incomplete outcome data (attrition bias) Diarrhoea durationLow riskOnly 2 out of 99 in the azithromycin group and 1 out of 99 in the ciprofloxacin group were not evaluated, the reasons were not specified.Incomplete outcome data (attrition bias) Stool volumeLow riskOnly 2 out of 99 in the azithromycin group and 1 out of 99 in the ciprofloxacin group were not evaluated, the reasons were not specified.Selective reporting (reporting bias)Low riskStudy outcomes were clearly specified and reported.Other biasUnclear riskStudy sponsor: academic, Pfizer supplied Azithromycin.[@CD008625-bbs2-0037]MethodsRandomized controlled trial.\
Follow up duration: not specified.ParticipantsLocation: Ankara, Turkey.\
Years: 1994.\
Participants: adults; 32% females.\
Number of participants: 90 randomized, 74 evaluated. Stool positive for *V .cholerae* required for inclusion.\
Cholera serogroup: O1.\
Exclusion due to previous use of antibiotics: not specified.\
Exclusion due to severity of symptoms: no.InterventionsPO Ciprofloxacin: 1 g single dose.\
PO Ciprofloxacin: 500 mg twice per day for 1 day.\
PO Doxycycline: 100 mg twice per day for 3 days.\
No treatment.\
Resistance to intervention: no resistance to Ciprofloxacin; resistance to Doxycycline not specified.OutcomesDiarrhoea duration in days (defined as: time until day of study when patient did not pass watery stool for 8 hours).\
Stool volume in mL/kg (definition not specified in study).\
Bacteriological failure (defined as: *V. cholerae* in stool after study day 4).\
Clinical relapse (defined as: re‐appearance of watery stool after a remission of 8 hours).\
Bacteriological relapse (defined as: re‐appearance of *V. cholerae* in stool after two negative stool exams).NotesEthics committee involved: not specified.\
consent requested and given from study participants: yes.\
Type of hydration used in study: IV hydration, ORS type not specified.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNo description.Allocation concealment (selection bias)Unclear riskNo description.Blinding (performance bias and detection bias) All outcomesHigh riskControl arm was given no treatment.Incomplete outcome data (attrition bias) Diarrhoea durationHigh riskA relatively large number of patients in each group (and a total of 16 out of 90) were not evaluated, reasons were not specified.Incomplete outcome data (attrition bias) Stool volumeHigh riskA relatively large number of patients in each group (and a total of 16 out of 90) were not evaluated, reasons were not specified.Selective reporting (reporting bias)Low riskStudy outcomes were clearly specified and reported.Other biasLow riskNo sponsor.[@CD008625-bbs2-0038]MethodsRandomized controlled trial.\
Follow up duration: 7 days minimum.ParticipantsLocation: Kolkata, India.\
Years: 1965 to 1966.\
Participants: adults. No females participated.\
Number of participants: number randomized not specified, 33 evaluated. Stool positive for *V .cholerae* required for inclusion.\
Cholera serogroup: O1.\
Exclusion due to previous use of antibiotics: yes.\
Exclusion due to severity of symptoms: no.InterventionsPO Tetracycline: 500 mg four times per day for 2 days.\
PO Tetracycline: 250 mg four times per day for 3 days.\
No treatment.\
Resistance to intervention: not specified.OutcomesDiarrhoea duration in hours (definition not specified in study).\
Stool volume in litres (definition not specified in study).\
Deaths (during study).\
Pathogen excretion duration in days (definition not specified in study).\
Clinical relapse (definition not specified in study).\
Bacteriological relapse (definition not specified in study).NotesEthics committee involved: not specified.\
consent requested and given from study participants: not specified.\
Type of hydration used in study: IV hydration, green coconut water.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskPreviously randomized schedule.Allocation concealment (selection bias)Unclear riskNo description.Blinding (performance bias and detection bias) All outcomesHigh riskControl arm was given no treatment.Incomplete outcome data (attrition bias) Diarrhoea durationUnclear riskNumber of patients randomized was not specified.Incomplete outcome data (attrition bias) Stool volumeUnclear riskNumber of patients randomized was not specified.Selective reporting (reporting bias)Unclear riskPrimary outcomes were not specified.Other biasLow riskStudy sponsor: academic.[@CD008625-bbs2-0039]MethodsRandomized controlled trial.\
Follow up duration: 7 days minimum.ParticipantsLocation: Kolkata, India.\
Years: 1965 to 1966.\
Participants: adults. No females participated.\
Number of participants: number randomized not specified, 33 evaluated. Stool positive for *V .cholerae* required for inclusion.\
Cholera serogroup: O1.\
Exclusion due to previous use of antibiotics: yes.\
Exclusion due to severity of symptoms: no.InterventionsPO Tetracycline: 2 g once per day for 2 days.\
PO Chloramphenicol: 500 mg four times per day for 3 days.\
PO Sulfaguanidine: 500 mg every four hours for 2 days; 2 g three times per day for 5 days.\
No treatment.\
Resistance to intervention: not specified.OutcomesDiarrhoea duration in hours (definition not specified in study).\
Stool volume in litres (definition not specified in study).\
Deaths (during study).\
Pathogen excretion duration in days (definition not specified in study).\
Clinical relapse (definition not specified in study).\
Bacteriological relapse (definition not specified in study).NotesEthics committee involved: not specified.\
consent requested and given from study participants: not specified.\
Type of hydration used in study: IV hydration, green coconut water.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High riskTreatment given alternately.Allocation concealment (selection bias)High riskTreatment given alternately.Blinding (performance bias and detection bias) All outcomesHigh riskControl arm was given no treatment.Incomplete outcome data (attrition bias) Diarrhoea durationUnclear riskNumber of patients randomized was not specified.Incomplete outcome data (attrition bias) Stool volumeUnclear riskNumber of patients randomized was not specified.Selective reporting (reporting bias)Unclear riskPrimary outcomes were not specified.Other biasLow riskNo sponsor.

Characteristics of excluded studies \[ordered by study ID\] {#CD008625-sec2-0018}
===========================================================

StudyReason for exclusion[@CD008625-bbs2-0040]Patients were not randomly assigned to treatment groups.[@CD008625-bbs2-0041]The article is not a controlled trial, and does not concern antimicrobial therapy.[@CD008625-bbs2-0042]An open, non‐comparative trial.[@CD008625-bbs2-0043]Patients were not randomly assigned to treatment groups.[@CD008625-bbs2-0044]Patients were not randomly assigned to treatment groups.[@CD008625-bbs2-0045]Patients were not randomly assigned to treatment groups.[@CD008625-bbs2-0046]The antimicrobial treatment used is unknown and is not used in practice. The supportive care described was inadequate.[@CD008625-bbs2-0047]Previous work by the same author raises questions regarding the quality of randomizations and risk of bias.[@CD008625-bbs2-0048]Patients were poorly matched in baseline, which raises questions regarding the quality of randomizations and risk for bias.[@CD008625-bbs2-0049]The trial described was an in vitro experiment.[@CD008625-bbs2-0050]Patients were not randomly assigned to treatment groups.[@CD008625-bbs2-0051]The publication is a review, not a trial.[@CD008625-bbs2-0052]The publication is a review, not a trial.[@CD008625-bbs2-0053]Not all study arms contain cholera patients.[@CD008625-bbs2-0054]Patients were not randomly assigned to treatment groups.[@CD008625-bbs2-0055]Patients were not randomly assigned to treatment groups.[@CD008625-bbs2-0056]The antimicrobial treatment is no longer used in practice.[@CD008625-bbs2-0057]Patients were not randomly assigned to treatment groups.[@CD008625-bbs2-0058]Patients were not randomly assigned to treatment groups.[@CD008625-bbs2-0059]Patients were not randomly assigned to treatment groups.[@CD008625-bbs2-0060]Patients were not randomly assigned to treatment groups.[@CD008625-bbs2-0061]The publication is an editorial letter, not a trial.[@CD008625-bbs2-0062]Patients were not randomly assigned to treatment groups.

Characteristics of studies awaiting assessment \[ordered by study ID\] {#CD008625-sec2-0019}
======================================================================

[@CD008625-bbs2-0063]MethodsUnknownParticipantsUnknownInterventionsDoxycycline 300 mg, single dose\
Tetracyline 500 mg four times per dayOutcomesUnknownNotesThis reference came up in the search conducted in *The Cochrane Library*:\
http://www.mrw.interscience.wiley.com/cochrane/clcentral/articles/179/CN‐00617179/frame.html.\
There are no UK holdings for the journal. This publication was requested as a World Wide Search by Caroline Hercod in December 2009; the search is still ongoing.

Characteristics of ongoing studies \[ordered by study ID\] {#CD008625-sec2-0020}
==========================================================

[@CD008625-bbs2-0064]Trial name or titleRandomized, Double Blind, Controlled Clinical Trial to Evaluate the Efficacy of Multiple‐Dose Ciprofloxacin With Single Dose Azithromycin Therapy for Adults With Cholera Due to Multiply Resistant Strains of V. Cholerae O1 or O13MethodsInterventional trial\
Allocation: randomized Endpoint classification: efficacy study Intervention model: parallel assignment Masking: double blind (subject, investigator) Primary purpose: treatmentParticipants18 to 60 year old males, duration of diarrhoea not exceeding 24 hours.InterventionsCiprofloxacin, twice per day for 3 days, dose not specified.\
Azithromycin, 1 g Azithromycin single dose.Outcomes[Primary Outcome Measures:]{.ul}\
To determine whether clinical success of therapy in the two treatment regimens are comparable.\
\[ Time Frame: 48 hours \]\
[Secondary Outcome Measures:]{.ul}\
Compare the rates of bacteriological success.Compare the diarrhoea duration.Compare stool volume of patients.Measure stool concentrations of the two drugs and compare them with MICs of *V. cholerae*.Record and compare adverse events.\
\[ Time Frame: 48 hours \]Starting dateJuly 2007Contact informationWasif A Khan, MBBS, MS (880‐2) 8860523‐32 ext 2348, wakhan\@icddrb.orgNotesContact with Dr. Khan regarding this trial was established on February 2010, at which point he was in the process of data handling and could not share information.[@CD008625-bbs2-0065]Trial name or titleRandomized, Open, Parallel Group Clinical Trial to Compare the Efficacy and Safety of a Single Dose of Ciprofloxacin Oral Suspension 20 Mg/Kg With a 3‐Day Course of Erythromycin Oral Suspension Administered in a Dose of 12.5 Mg/Kg Every 6 Hours (12 Doses) in the Treatment of Children,With Clinically Severe Cholera Due to *V. cholerae* O1 or O139.MethodsInterventional trial\
Allocation: randomized Endpoint classification: efficacy study Intervention model: parallel assignment Masking: open label Primary purpose: treatmentParticipantsAge: 2 to 15 years. Gender: male. Duration of illness: \< 24 hours. Written informed consent for participation in the study from either of the parents, or guardian, and oral assent from children aged 8 years.InterventionsCiprofloxacin Oral Suspension, 20 mg/kg, single dose.\
Erythromycin Oral Suspension, 12.5 mg/kg four times per day, for 3 days.Outcomes[Primary Outcome Measures:]{.ul}\
Rates of clinical success\
[Secondary Outcome Measures:]{.ul}\
Rates of bacteriologic success at test of cure visit.Duration of diarrhoea.Rates of clinical relapse.Rates of bacteriologic relapse.Duration of faecal excretion of *V. cholerae* O1 or *V. cholerae* O139.Measurements of six‐hourly volume of watery stool will be done for the period in which patients are hospitalized.Proportion of patients requiring unscheduled intravenous fluids.Frequency of vomiting and its volume.Frequency of stool per day.Frequency of vomit per day.Safety.PK‐assessment of serum and stool.Starting dateMay 2001Contact informationDebasish Saha, MBBS,MS, International Centre for Diarrhoeal Disease Research, Bangladesh, dsaha\@icddrb.orgNotesAn attempt to contact the author was made on February 2010.[@CD008625-bbs2-0066]Trial name or titleRandomized, Double‐Blind, Controlled Clinical Trial to Compare Efficacy of a Single Dose of Azithromycin Versus a Single Dose of Ciprofloxacin in the Treatment of Adults With Clinically Severe Cholera Due to *V. cholerae* O1 or O139MethodsInterventional trial\
Allocation: randomized Endpoint classification: efficacy study Intervention model: parallel assignment Masking: double blind Primary Purpose: treatmentParticipants18 to 60 year old males, duration of diarrhoea not exceeding 24 hours.InterventionsAzithromycin, single dose.\
Ciprofloxacin, single dose.Outcomes[Primary Outcome Measures:]{.ul}\
Clinical success.Bacteriological success.\
[Secondary Outcome Measures]{.ul}:\
Rates of clinical and bacteriologic relapse.Duration of diarrhoea in hours, and duration of faecal excretion of *V. cholerae* O1 or O139 in days.Volume of watery/liquid stool for each 6 and 24 hour of the study, and also the total amount of watery/liquid stools during the study period.Frequency of vomiting and the amount of vomitus, and proportion of patients with vomiting on each study day.Intake of oral and intravenous fluids for each 24 hour as well as the entire duration of the study.Proportion of patients with resolution of diarrhoea on each study day.Proportion of patients with a positive culture for infecting *V. cholerae* O1 or O139 on each study day.Starting dateDecember 2002Contact informationDebasish Saha, MBBS,MS, International Centre for Diarrhoeal Disease Research, Bangladesh, dsaha\@icddrb.orgNotesAn attempt to contact the author was made on February 2010.

YLK conducted the preliminary search. YLK and MP selected the studies for the review and extracted the data. AN and RB assisted in risk of bias assessment and the second revision. MAS was consulted where problems arose. YLK performed all necessary calculations for conversion of data and entered data into Review Manager 5. YLK and MP performed the data analysis. YLK and MP wrote the first draft of the review and all authors revised and wrote the final review.

Internal sources {#CD008625-sec2-0015}
================

None, Other.

External sources {#CD008625-sec2-0016}
================

None, Other.

None declared. Prof. Mohammed Abdus Salam is an author of some of the trials included in our review.

[^1]: Editorial Group: Cochrane Infectious Diseases Group.

[^2]: ^1^ Downgraded by 1 for risk of bias: in a sensitivity analysis restricted to the few trials at low risk of selection bias the effect size was smaller but remained statistically significant. ^2^ No serious inconsistency: statistical heterogeneity was high, however this related to the size of the effect seen with different antibiotics. For meta‐analysis within individual antibiotics statistical heterogeneity was low. ^3^ No serious indirectness: although many of the trials are now old, and drug susceptibility patterns have changed, these results are likely to apply to treatment with antibiotics to which the current *V. cholerae* isolates are susceptible. ^4^ No serious imprecision: both limits of the 95% CI represent statistically significant and clinically important effects. ^5^ Downgraded by 1 for serious risk of bias: only one study was at low risk of selection bias.

[^3]: ^1^ Downgraded by one for serious risk of bias: the study showing the largest effects had baseline imbalances which would favour azithromycin and was sponsored by a pharmaceutical company. The second trial was open label. ^2^ No serious inconsistency: statistical heterogeneity was high (I^2^ = 97%), but both studies found effects in favour of azithromycin and the heterogeneity was in the size of this effect. ^3^ No serious indirectness: one study was in children in India, one study was in adults in Bangladesh. ^4^ No serious imprecision: both studies found effects that were statistically significant and clinically important. ^5^ Downgraded by one for serious risk of bias: this single study had baseline imbalances which would favour azithromycin and was sponsored by a pharmaceutical company. ^6^ Downgraded by one for serious indirectness: only a single trial on adults in India assessed this outcome. ^7^ No serious imprecision: both limits of the 95% confidence intervals imply clinically important benefits. ^8^ Downgraded by one for serious inconsistency: a large effect was seen in the trial from India at high risk of bias; in the second trial, very few episodes of treatment failure were recorded, with both drugs performing well.

[^4]: ^1^ Downgraded by one for serious risk of bias: one study had high loss to follow‐up \> 25% in both groups, and one was sponsored by the drug manufacturer. ^2^ No serious inconsistency: statistical heterogeneity was high (I^2^ = 70%), but both studies found effects in favour of azithromycin and the heterogeneity was only in the size of this effect. ^3^ No serious indirectness: both studies were in children, with one study from India and one from Bangladesh. ^4^ No serious imprecision: both trials found statistically significant effects. ^5^ No serious inconsistency: statistical heterogeneity was low. ^6^ Downgraded by one for serious imprecision: the 95% CI is wide and includes important differences between drugs.

[^5]: ^1^ No serious risk of bias: one trial was at low risk of selection bias and this study found no effect consistent with the other two trials. ^2^ Downgraded by one for serious inconsistency: statistical heterogeneity is high (I^2^ = 66%), with one trial showing a benefit of six hours and two showing no effect. ^3^ No serious indirectness: the studies were conducted in children and adults in India and Bangladesh. Of note is that tetracycline was only given for two days in two of these trials. ^4^ No serious imprecision: the 95% CI probably excludes clinically important effects. ^5^ No serious risk of bias: one study was at low risk of selection bias and one was at unclear risk. ^6^ Downgraded by one for serious imprecision: the number of events is very low and underpowered to have confidence in this result.

[^6]: ^1^ Downgraded by one for serious risk of bias: only one trial was at low risk of selection bias; this study found no significant effect consistent with the other two trials. ^2^ No serious inconsistency: statistical heterogeneity is low (I^2^ = 0%). ^3^ No serious indirectness: the studies were conducted in children and adults in Bangladesh, Peru and Thailand. The most recent trial was conducted in 1996. ^4^ No serious imprecision: the 95% CI probably excludes clinically important effects. ^5^ Downgraded by one for serious imprecision: the 95% CI includes both clinically important effects and no difference. ^6^ Downgraded by one for serious imprecision: the number of events is very low and underpowered to have confidence in this result.

[^7]: ^1^ Downgraded by one for serious risk of bias: none of the trials concealed allocation adequately enough to be at low risk of selection bias. ^2^ No serious inconsistency: statistical heterogeneity is low (I^2^ = 31%). ^3^ No serious indirectness: the studies were conducted in children and adults in Bangladesh, Turkey and India. The most recent trial was conducted in 1994. ^4^ Downgraded by one for serious imprecision: all three trials are small and the overall 95% CI includes a mean difference of almost half a day. ^5^ Downgraded by one for serious risk of bias: only one of the trials concealed allocation adequately enough to be at low risk of selection bias. ^6^ Downgraded by one for serious imprecision: the 95% CI includes clinically important benefits and harms.

[^8]: ^1^ Downgraded by one for serious risk of bias: Only one trial adequately described a method of allocation concealment to prevent the risk of selection bias. ^2^ Downgraded by one for serious inconsistency: Statistically significant benefits were seen in one trial comparing Norfloxacin 400 mg twice daily for three days with 800 mg once only. Other comparisons did not find statistically significant differences. ^3^ Downgraded by 1 for serious imprecision: The number of events in these trials was very low and the trials were underpowered to detect differences. Although the meta‐analysis result is statistically significant, the 95% CI is wide and includes clinically important effects and unimportant effects.

[^9]: ^a^ Search terms used in combination with the search strategy for retrieving trials developed by The Cochrane Collaboration ([@CD008625-bbs2-0087]).

[^10]: Calculations performed with http://www.sealedenvelope.com. ^1^ The mean duration of diarrhoea in the control groups ranged from 29.3 to 127.2 hours ([Analysis 1.1](#CD008625-fig-00101){ref-type="fig"}). ^2^ The mean hydration requirements in the control groups ranged from 2.97 to 6 days ([Analysis 1.6](#CD008625-fig-00106){ref-type="fig"}).

[^11]: Calculations performed with http://www.sealedenvelope.com. ^1^ The overall proportion of clinical failures in people randomized to placebo or no treatment was 61% ([Analysis 1.4](#CD008625-fig-00104){ref-type="fig"}). ^2^ The overall proportion of clinical failures in people randomized to antibiotics was approximately was 12% ([Analysis 1.4](#CD008625-fig-00104){ref-type="fig"}). ^3^ Based on a RR of 0.5. ^4^ Based on a RR of 0.75. ^5^ The overall proportion of bacteriological failures in people randomized to placebo or no treatment was 74% ([Analysis 1.7](#CD008625-fig-00107){ref-type="fig"}). ^6^ The overall proportion of bacteriological failures in people randomized to antibiotics was approximately was 20% ([Analysis 1.7](#CD008625-fig-00107){ref-type="fig"}).
